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CHAPTER ONE: INTRODUCTION AND AIMS OF PROJECT 
 
1.1 INTRODUCTION  
 
Malnutrition is surprisingly common nowadays, especially in those who are unwell, 
and is both a cause and a consequence of ill-health. Many older people and those 
with any long term medical or psycho-social problems are chronically underweight 
and so are vulnerable to acute illness1. Parenteral nutrition has now become the 
accepted method for the prevention or correction of malnutrition in patients who 
cannot be provided with adequate nutrition by the gastro-intestinal route, and is an 
important therapeutic requirement in many clinical situations2.  
 
1.2 AIMS OF PROJECT 
 
The purpose of this diploma work was to obtain more punctual information on stability 
of the vitamins in parenteral nutrition admixtures depending on different storage 
conditions and different time. There is project which was done. 
 
Stability of the fat-soluble vitamins (A, E) and the water-soluble (B2, B6) vitamins 
which were added to the Kabiven® Peripheral Bag, firstly together with trace 
elements and secondly without trace elements.  
 
Assessing the chemical and physical stability was carried out after: 
 
 Zero time 
 7 days in a refrigerator followed by 24 hours and 48 hours storage at ambient 
temperature and protected from day-light. 
 14 days in a refrigerator followed by 24 hours and 48 hours storage at ambient 
temperature and protected from day-light. 
 29 days in a refrigerator followed 24 hours and 48 hours storage at ambient 
temperature and protected from day-light. 
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CHAPTER TWO: THEORETICAL PART 
 
2.1 PARENTERAL NUTRITION 
 
Parenteral Nutrition (PN) is an alternative method of providing nutritional support for 
patients via the intravenous route, the order methods being by the oral or enteral 
route. This intravenous route of administering artificial nutrition was pioneered by 
Dudrick et al (1968)3, who demonstrated for the first time, the access of administering 
concentrated glucose, amino acids and other essential nutrients towards growth 
development in both animals and man4. With advances in the various aspects of 
clinical medicine the need and indication for parenteral nutrition are increasing 
progressively. This is due to availability of better medical and surgical facilities to 
treat conditions which were lethal few years ago; increasing awareness of the 
importance of providing adequate nutrition and of the fact that in potentially curable 
situations patients may actually die because of malnutrition5.  
 
PN has now become the accepted method for the prevention or correction of 
malnutrition in patients who cannot be provided with adequate nutrition by the gastro-
intestinal route.  
Awareness of malnutrition in hospital patients is now increasing and recently, the 
National Institute for Health and Clinical Excellence (NICE) has issued a guideline 
that all hospital patients should be screened to identify those who are malnourished 
or at risk of malnutrition, and that nutrition support should be considered in these 
patients1. This guideline recommends that all hospital inpatients on admission and all 
outpatients at their first appointment should be screened (weight, measured and 
have Body Mass Index (BMI) calculated). For adult patients in hospital it is suggested 
to use the Nutrition Risk Screening 2002. Assessment should incorporate the 
following principles: 
 History and examination: to define all the factors leading to malnutrition and the 
likely natural history of the patient condition.  
 Disease status: this includes history, examination, bed-side measurements such 
as temperature, pulse rate and blood pressure, laboratory tests of inflammation 
including full blood count, albumin and C- reactive protein.  
 Laboratory tests: levels of vitamins, trace elements, changes in minerals. 
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 Fluid balance: examine for oedema or dehydration. 
 Functional assessment: ask the patient about exercise tolerance and breathing. 
Measure peak flow and muscle strength6. 
 
Malnutrition in hospitals is surprisingly common. Several studies have shown that up 
to 65% of patients admitted to medical and surgical wards are undernourished or 
become so during their stay. These patients are more likely to suffer from 
complications, they are more susceptible to infection and they experience delayed 
wound healing. Their mortality rates are higher and their stays in hospital longer. 
There is therefore increasing interest amongst health-care professionals in methods 
of providing nutritional support6.  
 
2.2 INDICATIONS FOR INTRAVENOUS NUTRITION 
 
Patients selected for PN are malnourished patients or patients who have the potential 
to become malnourished4. Nutrition support should be considered in people, as 
defined by a BMI of less then 18.5; unintentional weight loss greater then 10% within 
the last 3 - 6 months; or a BMI of less then 20 and unintentional weight loss greater 
than 5 % within the last 3 - 6 months1. Conditions which need parenteral nutrition 
support are for example conditions characterized by loss of bowel, conditions 
characterized by functional bowel failure, burns, severe septicaemia and multiple 
trauma with or without surgery5.  
 
2.3 ROUTES OF ADMINISTRATION OF PN  
 
PN means that nutrients are provided intravenously. Therefore venous access is 
necessary. PN can be administered via central route or via peripheral route7. 
 
2.3.1 Central Route  
 
PN has to be given via a catheter with tip located in a central vein to infuse nutrients 
at high concentrations and smaller volume. Most often the catheter is inserted into 
the superior vena cava. Central PN (CPN) is indicated to patients who require long-
term PN; those without adequate peripheral veins; those in whom peripheral PN 
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(PPN) has failed; who already have central venous access established; who have 
specific nutrition requirements and patients who are critically ill. PN for more than 7 
days is usually provided via a central vein because of the risk of thrombophlebitis 
caused by hyperosmolarity of nutrient solutions8. 
 
2.3.1.1 Central Venous Catheters (CVC) 
 
Nowadays CVCs are made of polyurethane or silicone. Some new CVCs are 
furthermore coated by antibiotics. Antibiotic-coated catheters have also been shown 
to result in significant reductions in infectious complication but have raised concern 
over the possibility of encouraging the growth of resistant organisms to the antibiotics 
employed. 
 
2.3.1.2 Peripherally Inserted Central Catheters (PICCs) 
 
These are usually inserted into either the cephalic or basilic vein in the cubital fossa. 
The catheter is advanced along the vein until the tip lies in the superior vena cava. 
Image post-insertion chest X-ray is mandatory for their safe use. These catheters are 
rapidly gaining in popularity. The use of PICCs carries the significant advantage that 
experience of direct puncture of central veins is not necessary. As with all CVCs 
these catheters must be inserted with strict attention to aseptic technique8. 
 
2.3.2 Peripheral Route 
 
The concept of peripheral parenteral nutrition (PPN) was first described in 1945 by 
Brunschwig and colleagues. The term peripheral refers to superficial veins, most 
often of the upper extremities. Peripheral veins of the lower extremities, especially in 
adults, are not suitable for PN. This access should be avoided because of higher 
risks of thrombophlebitis and because of the need of confirming the patient to bed. 
PPN is provided when catheterization of a central vein is impossible or 
contraindicated, when bacteraemia or catheter sepsis is present. The patients 
suitable for PPN are those with available peripheral veins, who need short-term 
therapy with low osmolar solutions. Unsuitable patients are those without available 
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peripheral veins, requiring high energy and protein, electrolyte intake or those at risk 
of fluid overloading and prolonged nutritional support7. 
 
2.4 COMPLICATIONS OF PN 
 
Complications can be categorized into two groups: Metabolic and Catheter related. 
Most of these complications can now be prevented or are easily treatable due to 
advances in modern medicine and clinical practice. 
 
2.4.1 Catheter-related Complications (CRC) 
 
CRC can be divided into three main categories: Mechanical Complications, 
Thrombosis and Catheter-related Sepsis. 
 
2.4.1.1 Mechanical Complications  
Mechanical complications include those that occur early, primarily related to 
subclavain catheter placement, and those occurring late with are primary related to 
the long-term presence of the central venous system. Pneumothorax is the most 
frequent complication associated with subclavain catheter placement.  
 
2.4.1.2 Catheter-related Sepsis  
Catheter-related sepsis still remains the most serious complication of total parenteral 
nutrition (TPN) in clinical practice today. The term ‘infection’, as related to the central 
vein catheter, is a universal term used to describe systematic or localized infections 
or the development of colonies along the length of the catheter. Systematic infections 
are frequently reported as catheter sepsis or bacteraemia. The material from which 
the catheter itself is made influences the risk of infection. Some materials favuor the 
collection of bacteria while others favour thrombogenesis. Materials which decrease 
thrombogenesis are PVC, polyethylene, polyurethane and silicone. The most 
important factor in prevention of this sepsis is aseptic technique.  
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2.4.1.3 Venous Thrombosis 
Venous thrombosis is a late complication which may occur after extended use of 
central venous system. Subclinical venous thrombosis occurs with a much frequency, 
approaching 50 %. Clinical subclavain vein thrombosis has been reported to be in 3 – 
7 %. The more rigid polyethylene catheters lead to thrombosis much more often and 
to a greater degree than much softer silicone and polyurethane catheters.  
 
2.4.2 Metabolic Complications 
 
The major deficiency states associated with prolonged use of TPN have been 
eliminated by recognizing requirements for the vitamins and trace elements. The 
most common metabolic complications are hypoglycaemia and hyperglycaemia.  
Hypoglycaemia is caused by sudden slowing of the glucose infusion. Over-secretion 
of endogenous insulin at high infusion rates can lead to an extraordinary form of 
hypoglycaemia. The most common cause of hyperglycaemia is rapid initiation of the 
infusion. Other metabolic complications are abnormalities in plasma electrolytes. 
They are minimized by careful monitoring. At least 50 mEq of sodium, 40 mEq of 
potassium, 90 – 100 mEq of phosphorus and 28 – 32 mEq of magnesium and 
calcium should be administered daily to all patients receiving PN. Trace metal 
deficiencies belongs to metabolic complications too. Zinc deficiency can develop in 
patients who are very catabolic or have excessive diarrhoea. Cooper deficiency has 
been observed in patients receiving home PN. Selenium is an essential element for 
humans. Chromium deficiency is likely to occur only in patients on long-term TPN 
with minimal or not oral intake. Essential fatty acid deficiency may be prevented by 
administration of between 4 – 6 % of the daily calories as either soybean or safflower 
oil fat emulsion. The main symptom of fatty acid deficiency is dry skin with small 
reddish papules and alopecia9. 
 
2.5 COMPONENTS OF PN ADMIXTURES 
 
PN admixture consists of three macronutrients: proteins as amino acid solutions, 
carbohydrates in the form of glucose, and fats in the form of lipid emulsions. 
Carbohydrates and fats provide the patients energy requirements. Included are the 
major electrolytes such as sodium, potassium, chloride, calcium, magnesium and 
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phosphate. The addition of micronutrients, including vitamins and trace elements, 
make a PN complete4. For mixtures which contain all described nutrients is used the 
term total parenteral nutrition (TPN).  
PN regimens may be compounded as either ‘two-in-one’ mixtures, which do not 
contain lipid emulsion, or ‘all-in-one’ mixtures (AIO), in which the lipid emulsion is 
included10. TPN administration has developed from separate macronutrients in 
infusion bottles to administration of the AIO bags. The mixing of all, or most, of the 
TPN components into a larger, usually 1 or 3 litre capacity, flexible container or Big 
Bag is now accepted as the safest and most convenient method of TPN 
administration. The packing of the different components of TPN mixture has 
important consequences. Certain constraints apply specifically to these solutions. 
Hypertonic dextrose infusions are made in flexible plastic containers, amino acids 
injections are produced in glass bottles because of their instability in most plastic 
containers, especially PVC, such solutions. Amino acid solutions are filled under 
vacuum and often contain a reducing agent to avoid oxidation of particular amino 
acids. Fat emulsions are produced under vacuum in glass bottles, again to avoid 
oxidation of fatty acids during long-term storage. Additives such as vitamins and 
trace elements are packed in ampoules or vials11. 
 
2.5.1 Carbohydrates 
 
Dietary carbohydrates usually provide between 40 – 70 % (currently recommended 
50 – 55 %) of our total daily energy intake. Glucose is the main source of readily 
available energy12, is supplied intravenously in the exact chemical form in which it is 
absorbed from the intestine. This glucose requirement is unique to humans and is 
about 145 – 160 g per day. Injured or septic patients may require more glucose than 
normal patients13. Adult glucose requirements in healthy subjects can be set at 4 – 5 
g/ kg/ day, equivalent to 50 % of the total energy requirement14.  
  
2.5.2 Proteins 
 
Proteins are large organic compounds made of amino acids arranged in a linear 
chain and joined together by peptide bonds. Therefore proteins are a source of 
amino acids. Traditionally, amino acids are classified into essential and non-
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essential. Essential amino acids in adults are histidine, leucine, isoleucine, lysine, 
methionine, phenylalanine, threonine, tyrosine, valine, tryptophan. Some of the non-
essential amino acids are alanine, arginine, glycine, glutamate, glutamine, serine and 
taurine15.  
 
Essential amino acids must be provided in the diet and should provide about 40 % of 
the total amino acid nitrogen. A daily intake of 12 – 16 g of nitrogen has been found 
to be adequate for most patients16. Some sick patients may be unable to synthesize 
amino acids which are considered to be non-essential in normal subjects. For 
example, histidine may not be synthesized in adequate amounts in patients with 
renal failure17. 
 
2.5.3 Lipids 
 
Lipids are very important energy substances and provide caloric requirements. They 
also serve as a source of essential fatty acids, such as linoleic and linolenic acid, 
which are necessary for the functioning of all tissues4. Lipid requirement is about 1 – 
1.5 g/ kg/ day in healthy adults14.  
 
Currently available intravenous emulsions consist of 10% or 20% emulsions of 
soybean or safflower oil. These are long-chain triglycerides (LCT), rich in omega-6 
polyunsaturated fatty acids (PUFA)4. New lipid emulsions are created medium-chain 
triglycerides (MCT) derived from palm kernel and coconut oil. MCT emulsions have to 
be administered either at very slow rates or together with LCT because of 
undesirable symptoms. Administration of an MCT/LCT mixture revealed in many 
cases advantages over an LCT. The current interest is in the use of fish oil and olive 
oil lipid emulsions. Olive oil contains a high level of monounsaturated fatty acids 
(MUFA) and fish oil is rich in n-3 fatty acids. There is the claim that n-3 fatty acids 
have anti-inflammatory and immunomodulatory effects13.  
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2.5.4 Micronutrients 
 
The term ‘micronutrients’ includes main classes of nutrient substances required in the 
diet in very small amount. These are the essential inorganic micronutrients or trace 
elements, and the vitamins or the essential organic micronutrients. The trace 
elements include zinc, cooper, selenium, manganese, chromium, molybdenum, iron, 
iodine and fluorine.  
 
The micronutrients have two main functions. Firstly they act as cofactors or 
coenzymes in enzyme catalyzed reactions. In general, the water-soluble vitamins 
have roles as coenzymes, taking an active part in enzyme catalyzed reactions. For 
both of these groups of substances, enzyme activity may be modulated by the 
availability of the micronutrient. In disease states, the metabolism of the major 
substances is significantly increased, and therefore the requirements for 
micronutrients are also increased. A second, micronutrient’s role is as part of the 
free-radical scavenging system. Oxidative metabolism generates a family of reactive 
oxygen species (superoxide, hydroxyl) and these have the potential to cause 
significant chemical damage18. Both vitamins and trace elements are discussed 
under Vitamins (see 2.6) and Trace elements (see 2.7). 
 
2.5.5 Fluids and Electrolytes 
 
The intake of fluid and electrolytes is an integral part of nutritional support. The 
calculation of appropriate requirements is necessary because electrolytes 
abnormalities may cause physiological and functional problems for the patients. 
Sodium, potassium, magnesium, calcium and phosphate are some of the major 
electrolytes required19. Daily requirements of each ion can vary widely, depending on 
the disease state and may be very high11.  
 
2.6 VITAMINS 
 
Vitamins are organic food components that promote the fast regular working of 
essential biochemical reactions within human body. These vitamins cannot generally 
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be synthesized in vivo, and must be obtained from food in trace amounts. They are 
required for growth, maintenance, lactation and reproduction20.  
 
Vitamins originally come from the term ‘vitamine’ as a generic descriptor for many 
such accessory factors associated with diets. This term was suggested by the Polish 
biochemist Casimir Funk. 
 
The vitamins are organic, low molecular weight substances that have key roles in 
metabolism. The vitamins are required in only small amounts in the diet because they 
are highly specific. They are classified according to their solubility into two groups - 
the fat-soluble vitamins or water-soluble vitamins. The fat-soluble vitamins include 
vitamins A, E, D, K these are soluble in non-polar solvents and have the potential for 
storage in the body. The water-soluble vitamins include ascorbic acid and the vitamin 
B group. They are soluble in polar solvents and are not stored in the body. They are 
excreted in the urine when present is excess of the body’s needs21. 
 
2.6.1 Water-soluble Vitamins 
 
2.6.1.1 Thiamine (Vitamin B1) 
 
 
 
Figure 2.1:  Chemical Structure of Thiamine 
 
Thiamine was first crystallized by Jansen and Donath in 1926. They named it 
aneurine, the antineuritic vitamin, because of its function in curing polyneuritis.  
Thiamine’s chemical structure contains a pyrimidine ring and a thiazole ring linked by 
a methylene bridge. Thiamine may be destroyed by several factors including neutral 
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and alkaline conditions, heat, oxidation, and ionizing radiation. It is stable at low pH 
(pH <7). Thiamin is stable during frozen storage. 
In foods derived from plants, thiamin occurs as free thiamin. In contrast, thiamin 
occurs in animal tissues almost entirely in phosphorylated forms. The predominant 
form being the coenzyme thiamin diphosphate, also called thiamin pyrophosphate 
(TPP). TPP is the coenzyme for the decarboxylases, the group of enzymes that 
remove carboxyl groups. One function of TPP is in the oxidative decarboxylation of 
pyruvate dehydrogenase. This is the key enzyme required for the conversion of 
pyruvate, the product of carbohydrate metabolism, to acetyl coenzyme A. Impaired 
entry of pyruvate into the citric acid cycle can lead to high concentrations of lactate 
and pyruvate, and to lactic acidodis4. 
 
Thiamin is widely distributed in foods, but in very low concentrations. The richest 
sources are yeasts and liver, especially pork liver. Cereal grains comprise the most 
important dietary sources of the vitamin in human diets21.  
 
Thiamine deficiency can result in beri-beri. This disease is prevalent in Southeast 
Asia, where polished rice is the dietary staple. Anorexia, cardiac enlargement, 
muscular weakness and lassitude are the general symptoms of beri-beri. This 
disease occurs in three clinical types. Dry (neuritic), wet (edematous), and infantile 
(acute) beri-beri21.  
 
Thiamine is degraded by a number of mechanisms. It is increasingly unstable as the 
pH rises and is decomposed by oxidizing or reducing agents. The reduction is 
caused in particular by sodium metabisulfite used as an antioxidant in some amino 
acids infusions. The route of degradation is showed at Figure 2.2. The rate of this 
cleavage increases with increased pH to a maximum rate of pH 6.  A couple studied 
confirmed that bisulfite at concentrations above 1 mmol/L caused thiamine 
degradation. There are some losses of thiamine after exposure to direct sunlight, but 
no significant losses after exposure to indirect daylight or fluorescent light22. 
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Figure 2.2: Thiamine Degradation Pathway 
 
 
 
2.6.1.2 Riboflavin 
 
 
Figure 2.3: Chemical Structure of Riboflavin 
 
Riboflavin, known as Vitamin B2, was discovered as a ‘yellow enzyme’ in yeast by 
biochemists Warburg and Christian in 193223. Riboflavin consists of an isoalloxazine 
derivate with a sugar alcohol ribityl side chain (Figure 2.3)4. Riboflavin is converted to 
its enzyme forms. The first step in this process is an ATP-dependent phosphorylation 
to yield riboflavin-5-phosphate, also called flavin mononucleotide (FMN). Most of 
FMN is then converted to the other coenzyme, flavin adenine dinucleotide (FAD), by 
FAD-pyrophosphorylase. FMN and FAD function as coenzymes for enzymes called 
flavoproteins or flavoenzymes, and acts as electron carriers in a variety of oxidation-
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reduction reactions. They are essential for the metabolism of carbohydrates, amino 
acids, and lipids. Some are also essential for the activation of the vitamins pyridoxine 
and folate to their coenzyme forms21. 
 
Riboflavin is widely distributed in foods. Rapidly growing, leafy, green vegetables are 
rich in the vitamin.  
 
Uncomplicated riboflavin deficiency becomes manifest in humans only after 3 - 4 
months of deprivation of the vitamin. Signs include cheilosis (inflammation of the 
lips), angular stomatitis (cracks at the corners of the mouth), glossitis (inflammation 
of the tongue), edema and hyperemia of the oral mucosa.  Although clinical signs of 
riboflavin deficiency are rarely seen, subclinical riboflavin deficiency is not 
uncommon. In children it may result in subnormal growth21. Riboflavin deficiency 
often coexists with nicotinic acid deficiency and can be complicated by pyridoxine 
deficiency4. 
 
Riboflavin is degraded by exposure to daylight, although it is less sensitive than 
retinol. In contrast the vitamin was not degraded by exposure to fluorescent light. 
Riboflavin has been reported to accelerate the photodegradation of certain amino 
acids. Enhanced degradation of methionine, tryptophan, proline, and tyrosine 
accelerated in the presence of riboflavin was reported during simulated infusion over 
a 24 hours period22. 
 
 
2.6.1.3 Niacin (Vitamin B3) 
 
 
 
Figure 2.4: Chemical Structure of Nicotinic Acid 
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The term niacin is the generic descriptor for nicotinic acid (pyridine-3-carboxylic acid) 
(Figure 2.4) and nicotinamide (nicotinic acid amide). The active coenzyme forms of 
niacin are nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine 
dinucleotide phosphate (NADP). In these both forms of the coenzymes is niacin 
essential24. NAD and NADP serve as coenzymes for a wide variety of reactions in the 
metabolism of carbohydrates, fatty acids and amino acids4. Niacin can be obtained 
from the diet or synthesised from amino acid tryptophan. This is an important route 
for meeting the body’s niacin requirement. To estimate nutritional intake or niacin 
equivalents from tryptophan, an average conversion ratio of 60 mg tryptophan to 1 
mg niacin was recommended by the Food and Nutrition Board of the National 
Research Council. The efficiency of conversion of dietary tryptophan to niacin is 
affected by a variety of nutritional and hormone factors. Deficiencies of vitamin B6, 
riboflavin, or iron slow the conversion because these micronutrients are essential 
cofactors for enzymes involved in the pathway24. 
 
Niacin is widely distributed in plant and animal foods. Good sources are yeast, 
meats, cereals, liver, and seeds.  
 
Pellagra is the classic dietary deficiency disease. This includes skin changes, 
nervous system and intestinal tract changes. The symptoms associates with the skin 
are most characteristic24. 
 
Both nicotinic acid and nicotinamide are very stable in dry form, but in solution 
nicotinamide is hydrolyzed by acids and bases21.  
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2.6.1.4 Pyridoxine (Vitamin B6) 
 
 
 
Figure 2.5: Chemical Structure of Pyridoxine 
 
Vitamin B6 is the generic descriptor for all 3-hydroxy-2-methylpyridine derivatives. 
This vitamin occurs naturally in three primary forms. Pyridoxine, which was called 
pyridoxol, its aldehyde pyridoxal and the amine pyridoxamine21. The bioavailability of 
vitamin B6 is affected by food processing and the amount of pyridoxine glucoside in 
foods. After intestinal absorption, the three forms are taken up by the liver and 
converted to pyridoxal 5-phosphate in a metabolic process which also involves 
riboflavin-containing coenzymes. Pyridoxal 5-phosphate serves as cofactor for > 100 
enzymes. These enzymes, which require pyridoxal 5-phosphate, influence several 
processes, including lipid metabolism, gluconeogenesis, niacin formation, nucleic 
acid metabolism and hormone modulation25. 
 
Vitamin B6 is occurring in greatest amount in meats, whole-grain products (especially 
wheat), vegetables and nuts. 
 
Although a frank deficiency of vitamin B6 is uncommon, marginal deficiencies are 
more likely. This is probably associated with a deficiency of other water soluble 
vitamins. It may be more adverse if there is also deficiency of riboflavin because 
riboflavin is involved in the metabolism of vitamin B6. The signs of deficiency are 
stomatitis, glossitis, cheilosis and depression25. 
 
Allwood M.C.11 reported that pyridoxine is also light sensitive although degradation is 
far less than is observed with vitamin A or riboflavin. Direct sunlight causes loss of 
pyridoxine, but it is stable during exposure to indirect daylight or fluorescent light22. 
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2.6.1.5 Folic Acid 
 
 
 
Figure 2.6: Chemical Structure of Folic Acid 
 
Folate is the generic descriptor for folic acid. Folic acid is also known as 
pteroylglutamic acid (PteGlu), consists of a pteridine nucleus coupled to para-
aminobenzoic acid (PABA), to become pteroic acid molecule, and conjugated with 
one to seven molecules of L-glutamic acid. The pteridine nucleus is composed of two 
rings, pyrazine and pyrimidine4. 
 
Dietary folates are absorbed as folic acid, 5-methyl-tetrahydrofolate and 5-formyl-
tetrahydrofolate. Tetrahydrofolic acid (FH4), active coenzyme, is the product of 
reduction of folic acid.  
 
Liver, mushrooms and green leafy vegetables are rich sources of folate. 
 
Deficiencies of folate result in impaired biosynthesis of DNA and RNA, and thus in 
reduced cell division. This is manifested clinically as anemia, dermatologic lesions 
and poor growth. Anemic individuals show weakness, headache, palpitations and 
difficulty in concentrating. Folate deficiency also affects the intestinal epithelium. This 
is manifested clinically as malabsorption or diarrhea21. 
 
Most folates are easily oxidized and, therefore, are unstable to oxidation under 
aerobic conditions of storage. Under such conditions FH4 derivatives can readily be 
oxidized to the corresponding derivatives of dihydrofolic acid (FH2) or folic acid.  
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Folic acid is insoluble in water and injections are formulated as sodium salt at pH 
above 8.0. After addition to TPN mixtures, there is a danger of free folate 
precipitation, especially in solutions below pH 4.5 – 5. FA in PN mixtures is 
compatible with plastic bags and sets. FA has been shown to be stable after 
exposure to indirect or direct daylight, and fluorescent light as well22.   
 
 
2.6.1.6 Vitamin B12  
 
Figure 2.7: Chemical Structure of Cyanocobalamin 
 
Vitamin B12 is an octahedral cobalt complex consisting of a porphyrin-like, cobalt-
centered macroring (called corrin ring), a nucleotide, and a second cobalt-bound 
group (e.g. H2O, CN
-, CH3). Vitamin B12 is the generic descriptor for all corrinoids (i.e. 
compounds containing the corrin ring) exhibiting the qualitative biological activity of 
cyanocobalamin (Figure 2.7)21. 
 
It is required by all DNA-synthesizing cells, including those of the hematopoietic and 
nervous system, and to facilitate the cyclic metabolism of folic acid. It transfers a 
methyl group from methylfolate, converting homocysteine to methionine26. There 
have been discovered three vitamin B12–dependent enzymes in animals: 
methylmalonyl-CoA mutase, leucine mutase and methionine synthetase. 
 
Vitamin B12 is synthesized by bacteria. It is found in the tissues of animals, which 
require the vitamin for growth. This vitamin is seldom found in foods derived form 
plants and is found only in foods that have been bacterially fermented and those 
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derived from the tissues of animals that have obtained it from their intestinal 
microflora.  
 
Vitamin B12 deficiency in human is characterized by megaloblastic anemia and, after 
prolonged periods, neurological signs. Those signs include peripheral neuropathy. 
This is characterized by dementia, memory loss and numbness of the hands. 
 
Vitamin B12 is very stable in both crystalline form and aqueous solution. However, the 
cobalamins are unstable to light21.  
 
 
2.6.1.7 Pantothenic Acid 
 
 
Figure 2.8: Chemical Structure of Pantothenic acid 
 
Pantothenic acid is widely distributed in foods. Therefore the problems with its 
deficiency are rare. It is converted in the body to CoA, the form in which it 
accomplishes most of its biological functions. Pantothenic acid plays the essential 
roles in the synthesis and acetylation of small molecules and in respiratory 
metabolism. Pantothenate is also required for the modification of numerous proteins 
with acetyl and fatty acyl groups27. 
 
The most important food sources of pantothenic acid are meats, broccoli, 
mushrooms and yeast.  
 
Pantothenic acid is yellow, viscous oil. Its calcium and other salts, however, are 
colorless crystalline substances. Each form is soluble in water and ethanol. Aqueous 
solutions of pantothenic acid are unstable to heating under acidic or alkaline 
conditions21. 
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2.6.1.8 Biotin 
 
Figure 2.9: Chemical Structure of Biotin 
 
Biotin is formerly known as vitamin H. This is widely distributed in food, but in very 
low concentrations. The most important natural sources of the vitamin are liver, milk 
and eggs. Because biotin is widespread among foods and is synthesized by the 
intestinal microflora, deficiencies are rare21.  
 
Biotin-dependent enzymes are involved in gluconeogenesis, biosynthesis of fatty 
acids, propionate metabolism and catabolism of leucine4. Biotin is unstable to 
oxidizing conditions and, therefore, is destroyed by heat, especially under conditions 
that support lipid peroxidation21. 
 
 
2.6.1.9 Ascorbic Acid (Vitamin C) 
 
Figure 2.10: Chemical Structure of Ascorbic Acid 
 
Vitamin C is the generic descriptor for all compounds that exhibit the biological 
activity of ascorbic acid (Figure 2.10). The oxidized form of this compound is called 
dehydroascorbic acid. Ascorbic acid (AA) is a dibasic acid. It forms salts, the 
aqueous solutions of which are strongly acidic. AA is a strong reducing agent and is 
oxidized under mild conditions to dehydroascorbic acid via the radical intermediate 
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semidehydroascorbic acid. The three forms (AA, semidehydroascorbic acid, 
dehydroascorbic acid) compose a reversible redox system. It is therefore an effective 
quencher of free radicals such as singlet oxygen. It reduces ferric (Fe3+) to ferrous 
(Fe2+) iron and the superoxide radical (O2
.-) to H2O2 and is oxidized to 
monodehydroascorbic acid in the process21. 
 
Vitamin C is required by only a few species which cannot synthesize it (human body). 
For most species, AA is a normal metabolite of glucose and is important for several 
physiological functions. Many of these functions involve redox characteristics that 
allow AA to play an important role in the antioxidant protection of cells. 
 
Vitamin C is widely distributed in food. Fruits, vegetables, liver and kidney are 
generally the best sources. For practical reasons, citrus and others fruits are good 
daily sources of vitamin C. Its acute deficiency results in scurvy in individuals unable 
to synthesize it. Signs of the disease occur primarily in mesenchymal tissues. 
Scorbutic individuals may show swollen, bleeding gums with tooth loss, impaired 
wound healing, and weakening of collagenous structures in bone21. 
 
Ascorbic acid is the least stable of all the vitamins added to TPN mixtures, although 
degradation of AA depends on a number of inter-related factors. AA is oxidized in 
aqueous solution by reaction with dissolved oxygen. The rate of degradation 
depends on various aspects of the solution. The most important factors are dissolved 
oxygen and the presence of catalysts, especially copper ions. Slow loss of vitamin C 
occurs during clinical administration of TPN mixtures if TE, especially copper, are 
excluded. If cooper is included, oxidation is accelerated.  The total amount of AA 
degraded depends on the oxygen content of the infusion and the volume of air 
remaining in the bag. A second stage of vitamin C degradation occurs due to the 
permeation of oxygen through the plastic. Some degradation will be also occurs in 
the administration set for the same reasons11. Allwood M.C.11 also reported that 
cysteine and cystine inhibit the catalytic effect of copper, therefore, if infusion 
includes amino acids, degradation rates can be lower.  
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Figure 2.11: The Degradation of AA in the Presence of Oxygen 
 
 
Dehydroascorbic acid is metabolically active. Therefore if the reaction proceeds only 
to this point, the availability of vitamin C is unaffected. The oxidation of AA clearly 
proceeds rapidly to inactive products. There is the potential appearance of oxalic acid 
(OA) in the mixture as and stage degradation product. The potential toxicity of this 
reaction may be significant11. In vivo OA is normally excreted in urine as a waste 
product of intermediary metabolism, but may precipitate with calcium in urine or soft 
tissues. Calcium oxalate precipitation deposition plays a role in urolithiasis, renal 
failure and the systemic oxalosis of certain inborn errors of metabolism. In patients 
receiving long-term TPN has been reported hyperoxaluria, elevated serum oxalate 
concentration, and systemic oxalosis because of degradation of parenteral AA. 
Oxalogenesis from AA oxidation in TPN solutions has been reported to cause 
catheter occlusion. Oxalate itself is not stable in dilute solution and degrades to 
carbon dioxide and formic acid under UV light28. 
 
2.6.2 Fat-soluble Vitamins 
 
2.6.2.1 Vitamin A  
 
Vitamin A is the generic descriptor for compounds with the qualitative biological 
activity of retinol (Figure 2.12). They are called retinoids. 1 international unit (IU) 
vitamin A activity is equivalent to 0.3 g all-trans-retinol. Some compounds of the 
class of plant pigments called carotenoids and also have vitamin A activity. These 
are called provitamin A carotenoids and include -carotene21. 
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Figure 2.12: Chemical Structure of Retinol 
 
Vitamin A is usually used in the form of esters such as the acetate, propionate and 
palmitate4.  
Vitamin A can support the maintenance of healthy epithelial cells differentiation, 
normal reproductive performance, and visual function. Vitamin A appears to have a 
role in maintaining the normal health of the skin. Its deficiency causes the skin to be 
thick, dry and scaly. Several carotenoids have been shown to have direct antioxidant 
activities. These include -carotene, lycopene and lutein21. 
 
Deficiency of vitamin A can lead to night blindness and condition called 
xerophthalmia, or dryness of the eye4. 
 
Retinol is the most light-sensitive of the vitamins22. Retinol is known to be rapidly 
broken down by exposure to UV light. Therefore, daylight causes rapid degradation11. 
Photolysis proceeds both in the bag and during passage through the administration 
set. Administration in a room with only artificial lighting will lead to minimum 
degradation. 
 
Sorption of retinol has been reported, but it depends on the ester used. Whereas the 
acetate ester binds strongly to PVC bags and administration sets, the palmitate ester 
shows no evidence of binding to plastics used to store or administer PN22. The 
presence of amino acids and fat emulsion in the bag affords considerable 
protection11. 
 
 
2.6.2.2 Vitamin D 
 
Vitamin D is the generic descriptor for all steroids exhibiting qualitatively the 
biological activity of cholecalciferol. Ergocalciferol (Figure 2.13) (vitamin D2) is found 
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in plants, fungi, and lichens while cholecalciferol (Figure 2.14) (vitamin D3) is widely 
distributed in animals. Tissue cholecalciferol concentrations are dependent on the 
vitamin D content of the diet and the exposure to sunlight. Vitamin D is formed in 
animals by the action of UV light on 7-dehydrocholesterol in the skin. The activation 
reaction depends on the absorption of UV light by the steroid B ring of the sterol 
nucleus, and involves the opening of that ring in the formation of provitamin D3 
21. 
  
 
  
 
Figure 2.13: Chemical Structure of Figure 2.14: Chemical Structure of  
Ergocalciferol Cholecalciferol    
 
  
The rich sources of vitamin D3 are fish liver and oil.  
 
Vitamin D functions as a steroid hormone. Its physiological role is the maintenance of 
calcium and phosphate homeostasis, impairment of which produces the lesions in 
bone called rickets and osteomalacia21. 
 
Gillis et al. reported that vitamin D may be strongly bound to plastic. Sorption to the 
administration set and bag can be significant.  
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2.6.2.3 Vitamin E 
 
Vitamin E is the generic descriptor for all tocoretinol derivates that exhibit qualitatively 
the biological activity of -tocopherol (Figure 2.15). Synthetic preparations of vitamin 
E presently available are mixtures of all eight possible stereoisomers. The acetate 
esters are used in medicine and animal feeding, whereas the unesterified forms are 
used as antioxidants in foods and pharmaceuticals. Other forms are also used in 
multivitamin preparations. 
 
 
Figure 2.15: Chemical Structure of -tocopherol 
 
Vitamin E has a role in the normal metabolism of all cells. It serves as an antioxidant 
and its function involves the reduction of free radicals21. Because of its antioxidative 
properties, vitamin E is believed to prevent diseases that are associated with 
oxidative stress such as cardiovascular disease, cancer and neurologic disorders4. 
 
Tocopherol appears to be relatively stable in PN mixtures22. But Gillis29 reported that 
vitamin E and D may be strongly bound to plastic. Sorption to the administration set 
and bag can be significant. Vitamin E together with Vitamin A are the most light 
sensitive vitamins. Vitamin E degrades by photo-oxidation30. 
 
 
2.6.2.4 Vitamin K 
 
Vitamin K is the generic descriptor for 2-methyl-1,4-naphthoquinone and all of its 
derivatives exhibiting qualitatively the biological activity of phylloquinone. Naturally 
occurring forms of the vitamin have unsaturated isoprenoid side chain at C-3 of the 
naphthoquinone nucleus. The phylloquinone group includes forms with phytyl side 
chain and is called vitamin K1 (Figure 2.16). The menaquinone group have side chain 
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composed of a varying number of isoprenoid residues. The menaquinone (Figure 
2.17) is called vitamin K2 and is synthesized by bacteria. The compound without a 
side chain is called menadione. It does not exist naturally and is the compound of 
commerce, because is made in several forms (e.g. menadione sodium bisulfite 
complex, menadione dimethylpyrimidinol bisulfite)21. 
 
 
Figure 2.16: Chemical Structure of Phylloquinone 
 
 
Figure 2.17: Chemical Structure of Menaquinone 
 
Vitamin K is used by bacteria and plants, which can synthesize it, for electron 
transport and energy production. Animals cannot synthesize the vitamin, but 
require it for blood clotting and bone formation. Vitamin K reduces risks to 
postsurgical thrombosis and cardiac patients. Warfarin and dicumarol and other 
inhibitors of the vitamin K oxidation/carboxylation/reduction cycle are valuable in 
this purpose. Vitamin K has clear roles in the metabolism of calcified tissues. 
 
There are two natural sources of vitamin K. Green plants synthesize the 
phylloquinones and bacteria (include those of the normal intestinal microflora) 
synthesize the manaquinones. Green leafy vegetables tend to be rich in vitamin 
K, whereas fruits and grains are poor sources
21
. 
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Vitamin K deficiency is rare among humans. It is because of the significant 
microbial synthesis of the vitamin that occurs in the intestines. But neonates are 
at special risk of vitamin K deficiency for several reasons: 
o Placental transport of the vitamin is poor 
o The neonatal intestine is sterile for the first few days of life 
o Human milk is an inadequate source of vitamin K 
o Hepatic biosynthesis of the clotting factors is inadequate in the infant
21
.  
 
 
2.7 TRACE ELEMENTS (TE) 
 
TE are an essential additive to PN mixtures. Currently considered necessary TE 
include copper, zinc, manganese, iron, iodine, fluorine, chromium, selenium and 
molybdenum. It is also recognized, that TE are present in variable quantities as 
contaminants31. For example zinc can be extracted from rubber stoppers used in 
glass bottles and from PVC additives11. Aluminium (AL) is a contaminant of several 
substances, such as calcium and phosphate salts and albumin32. 
 
Chromium, copper, iron, manganese, zinc and selenium are routinely added to TPN 
solutions to avoid the development of deficiency manifestations32. 
 
In healthy subjects, TE are present in the organism at very low levels. However, they 
are involved in a number of key metabolic functions. Some of the best known TE are 
considered as essential because of their role in maintaining important enzymatic and 
metabolic functions. Among them are copper, iron and zinc. Some of TE are 
enzymatic cofactors, vitamin cofactors, or hormone cofactors. Many act as 
antioxidants2.  
 
2.7.1 Zinc 
 
Zinc (Zn) is a small ion (0.065nm) and has a concentrated 2+ charge (Zn2+). It is a 
strong Lewis acid (electron acceptor).  
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Zinc has catalytic, structural and regulatory function in biology. Catalytic roles are 
found in enzymes from all six classes of enzymes. Examples are the RNA nucleotide 
transferases (RNA polymerases I, II, III), alkaline phosphatase and the carbonic 
anhydrases33. Approximately 100 enzymes require zinc for their catalytic activity, 
especially the enzymes of protein and nucleic acid synthesis. Zinc also permits the 
folding of other proteins by binding to cysteine and histidine residues, forming zinc 
fingers. These have roles in controlling gene transcription. Zinc is absorbed after 
digestion of macronutrients in the gut. Absorption may be markedly affected by 
ingestion of large amounts of other elements such as iron or cooper. Zinc deficiency 
is well characterized. Reduced growth in children is early sign. Severe zinc deficiency 
gives rise to alopecia, diarrhoea, skin rash especially on the face and impaired 
appetite34. 
 
2.7.2 Copper  
 
Copper (Cu) is a transition metal widely distributed in nature. In solution, as well as in 
living organisms, cooper is found almost exclusively in the +2 and +1 valence states. 
At neutral pH in aqueous media copper ions form hydroxides that precipitate out of 
solution unless chelated by organic molecules35. 
 
Copper has primarily a catalytic role for certain metalloenzymes, which act as 
oxidases. For example, cytochrome C oxidase is especially important in energy 
metabolism. Copper is transported in plasma bound to caeruloplasmin, which 
participates in tissue iron release. Deficiency of cooper is rare, but it has been 
observed in TPN and causes normocytic hypochromic anaemia, neutropenia and 
skeletal disturbances34. 
 
2.7.3 Iron  
 
Iron (Fe) is the fourth most common element on earth after oxygen, silicon and 
aluminium. In aqueous solution iron exists in two oxidation states, Fe2+, the ferrous 
form, and Fe3+, the ferric form36. 
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In the adult human body, over half the iron is present in haemoglobin and in iron-
binding proteins, such as myoglobin, transferrin, lactoferrin, ferritin, and hemosiderin. 
The remainder occurs in various enzymes. The main function of Fe in the body is 
oxygen transport within the blood and muscle32. 
 
Iron is stored in the liver and bone marrow in the form of ferritin34. Fe deficiency 
develops quite slowly, because the Fe stores in the body can suffice for up to one 
year. Those who develop true Fe deficiency anaemia due to blood losses from an 
ulcer, a malignant tumor, or during excessive menstrual flow, require Fe 
supplementation. In contrast, hospitalized patients who develop anaemia due to 
chronic inflammation or infections have low serum Fe, but adequate stores32.  
 
2.7.4 Selenium  
 
Selenium (Se) plays a structural role as a constituent of selenoproteins, and enzymic 
role as part of many key antioxidant enzymes such as glutathione peroxidase, as 
selenocysteine4.  
 
Se deficiency may result in different clinical outcomes. A fatal cardiomyopathy due to 
Se deficiency, mainly in children, was described in the Keshan district of China, 
where Se levels are very low in the soil and in foods. Supplementation with sodium 
selenite corrected this problem. Similar cases of fatal cardiomyopathy have been 
reported in adult patients receiving long-term TPN without Se supplementation32. 
 
Absorption of Se from the diet is very efficient – much is in the form of 
selenomethionine or selenocysteine. Commercial selenium supplements in the form 
of selenite or selenate are well absorbed. It seems likely that selenium deficiency 
alone does not cause obvious illness34.  
 
2.7.5 Chromium 
 
Trivalent chromium (Cr) is an essential TE for improved glucose tolerance, but 
hexavalent Cr has been shown to be a carcinogen. Normally, all circulating Cr is 
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trivalent32. Cr increases the action of insulin, possibly through amplifying insulin 
receptor tyrosine kinase activity. Cr is absorbed largely in the form of Cr3+ 34. 
 
A very small number of cases of chromium deficiency have been observed during 
TPN. Subclinical deficiency may lead to impaired glucose tolerance in type 2 
diabetes. Assessment of Cr status is extremely difficult due to very low plasma 
concentrations34. 
 
2.7.6 Molybdenum 
 
Molybdenum (Mo) is a co-factor for several oxidiser enzymes, especially sulphite 
oxidase and xanthine oxidase34. 
 
A case of Mo deficiency was reported in an adult receiving long-term TPN, who 
developed intolerance to infused amino acids, elevated serum methionine, 
decreased serum uric acid, and low urinary excretion of sulphate. Supplementation of 
ammonium molybdate corrected these biochemical abnormalities. Mo has a low level 
of toxicity32. 
 
 Assessment is rarely done. Plasma concentration is very low and difficult to measure 
34.  
 
2.7.7 Manganese 
 
Manganese (Mn) is associated with many enzymes, such as Mn-superoxide 
dismutase (antioxidant protection) and pyruvate carboxylase (energy metabolism). 
Deficiency of Mn can impair the production of hyaluronic acid, chondroitin sulphate 
and other mucopolysaccharides needed for growth and maintenance of connective 
tissue, cartilage and bone. Mn deficiency may not be evident in some patients on 
TPN because Mn can be derived from the contaminants present in the parenteral 
fluids. 
 
Mn is excreted through the bile. Patients with cholestatic liver disease should not be 
given supplements of this metal32. 
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2.7.8 Other TE 
 
Cobalt (Co) is required as a component of vitamin B12 and is provided as 
cyanocobalamin at a dosage of 1 g/day for children in TPN preparations. Iodine is 
an integral part of the thyroid hormones, thyroxine and triiodothyronine. Deficiency of 
iodine leading to thyroid enlargement and goiter development are prevented in adults 
by a daily oral intake of approximately 150 g iodine. 
 
 
2.8. MICRONUTRIENT REQUIREMENTS 
 
There is the difficulty in establishing recommendations for intakes of micronutrients in 
health and disease. The problem is not too difficult for those micronutrients (water-
soluble vitamins) where there is a wide safety margin between effectiveness and 
toxicity. However, fat-soluble vitamins and for many TE (such as Se) there is a 
relatively narrow margin of safety and caution is required to prevent over-dosage. 
This is also true for nutrients where homeostasis achieved by controlling absorption 
from the gut18. 
 
Parenteral vitamins requirements differ from enteral nutrition requirements, where 
enteral are designed for healthy individuals to prevent deficiencies and to minimise 
the risk from nutrition-related chronic disease. Dosing guidelines for parenteral 
vitamins are approximates to the needs of patients with increased requirements in 
acute and chronic disease4. 
 
Table 2.1: Daily Parenteral Vitamin Requirements in Adults18 
 
Vitamins Adults parenteral requirements 
Vitamin A 1000 µg 
Vitamin D 5 µg 
Vitamin E 10 mg 
Vitamin K 150 µg 
Thiamine 3.0 mg 
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Riboflavin 3.6 mg 
Pyridoxine 4.0 mg 
Niacin 40 mg 
B12 5 µg 
Folic acid 400 µg 
Biotin 60 µg 
Ascorbic acid 100 mg 
 
 
Table 2.2: Daily Parenteral TE Requirements in Adults18 
 
Trace elements Adults parenteral requirements 
Zn 3.2 – 6.5 mg 
Cu 0.3 – 1.3 mg 
Se 30 – 60 µg 
Mn 0.2 – 0.3 mg 
Cr 10 – 20 µg 
Mo 19 µg 
Fe 1.2 mg 
I 131 µg 
F 0.95 mg 
 
 
Commercial vitamins for PN are commonly available as multivitamin formulations 
such as Solvitio® N (Fresenius Kabi), Cernevit® (Baxter), Vitlipid® N Adult 
(Fresenius Kabi) and Vitlipid® N Infant (Fresenius Kabi) injections. Multiple TE are 
now available in a formulation such as Additrace® (Fresenius Kabi) and Decan® 
(Baxter) for adults, and Peditrace® (Fresenius Kabi) for paediatrics4. 
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2.9 POTENTIAL INTERACTIONS OF COMBINED TPN MIXTURES IN BIG BAGS 
 
Mixing TPN components, which include glucose, lipids, amino acids, electrolytes, 
vitamins and TE, provides a chemically unstable mixture with many possible 
reactions occurring37. These reactions include precipitation and degradation of 
particular compounds. Exposure to light may cause degradation while temperature 
changes can result in precipitation. pH changes can lead to significant loss of stability 
or to precipitation. The filling process is important as well because causes aeration of 
solutions and increasing concentrations of dissolved oxygen. Poor mixing can lead to 
local concentration effects resulting in chemical reaction11. 
 
2.9.1 Amino Acid Stability  
 
Amino acids retain their stability after dilution in TPN mixtures for at least 28 days if 
stored in the refrigerator. They are also stable during exposure to normal levels of 
artificial light or daylight. However, exposure to intense artificial light from a 
phototherapy unit in neonatal care may cause accelerated degradation of glycine and 
leucine. In the presence of riboflavin, photo-oxidation of several amino acids is 
accelerated11.  
 
2.9.2 Electrolytes 
 
The principal electrolytes necessary for nutritional support are sodium, potassium, 
calcium, magnesium, chloride, acetate and phosphate. Daily requirements of each 
ion can vary widely and depending on the disease state. It may be very high. The 
major physical-chemical incompatibility, causing precipitation, occurs when high 
concentrations of calcium and phosphate are mixed together. As the pH rises, more 
dibasic phosphate becomes available to react with calcium ions to form the 
precipitate. At low pH the monobasic ion predominates, being a far more soluble salt, 
precipitation is unlikely to occur. The most important factor influencing the maximum 
solubility of calcium + phosphate added to TPN mixtures is, therefore, pH. Practical 
considerations are also important. It is necessary to add and dilute the phosphate 
salt before adding calcium ions to maximize the solubility of the two ions of TPN 
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mixtures. Other additives such as TE and vitamins appear to have no effect on the 
solubility of calcium phosphate11. 
 
2.9.3 Trace Elements (TE) 
 
The addition of TE may lead to numerous physical, chemical and nutritional 
interactions especially between vitamins and TE, or amino acids and TE. But the 
addition of some TE does not seem to alter the stability of a parenteral mixture2. TE, 
in particular copper and iron, may interact with complete PN mixtures leading to 
precipitate formation. According to Allwood M.C.22 results, copper sulphide 
precipitated most rapidly in PN mixtures containing Vamin 9 ® and in mixtures stored 
in multilayered bags. Copper sulphide precipitation was delayed in PN mixtures 
containing Vamin 14 ® and was not observed in PN mixtures stored in EVA bags. 
Iron phosphate precipitates were observed in Synthamin®-containing PN mixtures 
after storage, but this was prevented in mixtures containing vitamins stored in 
multilayered bags. From this study result that stability of TE in TPN depends on 
source of amino acids and type of used container as well.  
 
There is an important interaction between Se and vitamin C and E. Se is combined 
with both of them due to its anti-oxidative role. It protects the cells against oxygen 
radicals, especially on the lipoprotein membranes2. Harraki2 reported that the 
absorption of Se was much decreased when sodium selenite and ascorbic acid were 
provided orally together.  
 
2.9.4 Vitamin Stability 
 
Vitamins are generally believed to be among the least stable ingredients in PN 
mixtures, and it is recommended that they should be added immediately before 
commencing infusion or that infusion should be commenced within 24 – 28 hours of 
addition. Some vitamins can undergo degradation during administration. The major 
physico-chemical considerations are exposure to light, the type of plastic used to 
manufacture the PN container and infusion equipment, and storage temperature. The 
most important cause of vitamin losses in PN mixtures is chemical degradation22. 
Stability of particular vitamins was discussed in detail under Vitamins (see 2.6).  
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CHAPTER THREE: EXPERIMENTAL PART 
 
3.1 INTRODUCTION 
 
This chapter describes materials used for tests, preparation of the samples and 
physical instruments used for physical analysis of the vitamins. Chemical assays of 
the vitamins by High Performance Liquid Chromatography (HPLC), and statistical 
analysis are explained as well.  
 
3.2 MATERIALS 
 
Table 3.1: Used Materials, Manufacturers and Expiry Dates 
 
Materials Manufacturer Expiry Date 
Kabiven® Peripheral Bag 
900 kcal/5gN, Emulsion for 
infusion, 1440 ml 
Fresenius Kabi Limited, 
Runcorn, Cheshire, U.K. 
11/2008 
Vitlipid® N Adult, 
Concentrate for emulsion 
for infusion, 10 ml 
Fresenius Kabi Limited, 
Birchwood, Warrington, 
U.K. 
10/2008 
Solvitio® N, Powder for 
concentrate for solution for 
infusion 
Fresenius Kabi Limited, 
Runcorn, Cheshire, U.K. 
01/2009 
Additrace®, Concentrate 
for solution for infusion, 10 
ml 
Fresenius Kabi Limited, 
Runcorn, Cheshire, U.K. 
01/2009 
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Kabiven Peripheral 900 kcal/5gN 
Emulsion for infusion, 1440 ml 
1. Glucose 11% 885 ml contain: Glucose anhydrous 97 g, Water for injections to 885 
ml 
2. Vamin 18 300ml contain: Alanine 4.8 g, Arginine 3.4 g, Aspartic acid 1.0 g, 
Glutamic acid 1.7 g, Glycine 2.4 g, Histidine 2.0 g, Isoleucine 1.7 g, Leucine 2.4 g, 
Lysine 2.7 g, Methionine 1.7 g, Phenylalanine 2.4 g, Proline 2.0 g, Serine 1.4 g, 
Threonine 1.7 g, Tryptophan 0.57 g, Tyrosine 0.07 g, Valine 2.2 g, Calcium chloride 
0.22 g, Sodium glycerophosphate anhydrous 1.5 g, Magnesium sulphate 0.48 g, 
Potassium chloride 1.8 g, Sodium acetate 1.5 g, Water for injections to 300ml. 
Glacial acetic acid q.s. to pH approx. 5.6 
3. Intralipid 20% 255 ml contain: Purified soybean oil 51 g, Purified egg 
phospholipids 3.1 g, Glycerol 5.6 g, Water for injections to 255 ml, Sodiun hydroxide 
q.s. to pH approx. 8 
Electrolytes in total: Sodium 32 mmol, Potassium 24 mmol, Magnesium 4.0 mmol, 
Calcium 2.0 mmol, Phosphate 11 mmol, Sulphate 4.0 mmol, Chloride 47 mmol, 
Acetate 39 mmol 
 
Vitlipid N Adult 
Concentrate for emulsion for infusion 
10.0 ml contains:  
Active ingredients: Retinol (as palmitate) (Vitamin A) 990 g, Ergocalciferol (Vitamin 
D2) 5 g, d1-alpha-tocopherol (Vitamin E) 9.1 mg, Phytomenadione (Vitamin K) 
150g 
Inactive ingredients: Fractionated soybean oil 1.0 g, Fractionated egg phospholipids 
120 mg, Glycerol 225 mg, Sodium hydroxide q.s., Water for injection to 10.0 ml 
 
Solvitio N 
Powder for concentrate for solution for infusion 
1 vial contains 484 mg powder 
Active ingredients: Thiamine Nitrate 3.1 mg, Sodium riboflavine phosphate 4.9 mg, 
Nicotinamide 40 mg, Pyridoxine hydrochloride 4.9 mg, Sodium pantothenate 16.5 
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mg, Sodium ascorbate 113 mg, Biotin 60 micrograms, Folic acid 0.4 mg, 
Cyanocobalamin 5.0 micrograms 
Inactive ingredients: Methyl parahydroxybenzoate 0.5 mg, Glycine 300 mg, Disodium 
edetate 0.5 mg 
These correspond to: Vitamin B1 2.5 mg, Vitamin B2 3.6 mg, Nicotinamide 40 mg, 
Vitamin B6 4.0 mg, Pantothenic acid 15.0 mg, Vitamin C 100mg, Biotin 60 g, Folic 
acid 0.4 mg, Vitamin B12  5.0 g 
 
Additrace 
Concentrate for Solution for Infusion  
10.0 ml contains: 
Active ingredients: Ferric chloride 20 micromol, Zinc chloride 100 micromol, 
Manganese chloride 5 micromol, Copper chloride 20 micromol, Chromic chloride 0.2 
micromol, Sodium selenite 0.4 micromol, Sodium molybdate 0.2 micromol, Sodium 
fluoride 50 micromol, Potassium iodide 1 micromol. 
Inactive ingredients: Xylitol 3 g, Hydrochloric acid q.s., Water for injections to 10 ml. 
 
Table 3.2: Reagents and Suppliers 
 
Reagent Supplier 
Methanol (HPLC grade) 
Fisher Scientific U.K. 
Loughborough, Leicestershire 
Orthophosphoric acid 
(Analytical reagent grade) 
Fisher Scientific U.K. 
Loughborough, Leicestershire 
diPotassium hydrogen 
orthophosphate trihydrate 
K2HPO4 . 3H2O 
Fisher Scientific U.K. 
Loughborough, Leicestershire 
Barnstead Nanopure water 
Barnstead Thermolyne Corporation, 
Dubuque, Iowa 
pH 7 Buffer 
Fisher Scientific U.K. 
Loughborough, Leicestershire 
Potassium dihydrogen 
orthophosphate (HPLC grade) 
Fisher Scientific U.K. 
Loughborough, Leicestershire 
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Table 3.3: Sterile Equipment 
 
Sterile equipment Supplier 
BD Microlance 3 Needles 19G, 21G 
and 23G 
Becton Dickinson 
BD Plastipak Syringes 1-20 ml Becton Dictinson 
 
 
Table 3.4: Instruments 
 
Instruments Manufacturer 
HPLC system Thermo Spectrasystem 
Orion Model 420A 
pH/mV/Temperature Meter 
Beverly, MA, USA 
The Advanced Osmometer Model 
3D3 
Advanced Instruments, inc., 
Massachusetts, USA 
Weighing balance Sartorius Model 
A02 
Sartorius AG, Goettingen, Germany 
Microflow laminar flow cabinet, 
horizontal 
Bioquell UK Limited, Andover, Hants 
Pharmaceutical refrigerator 
Lec Refrigeration, Prescot, 
Merseyside 
Light microscope Olympus BH-2 Olympus Optical Co. Limited, Tokyo 
Autosampler 2.0 ml amber vials 
Fisher Scientific U.K. 
Loughborough, Leicestershire 
Disposable Pasteur pipettes, 3 ml 
Elkay Laboratory Products Ltd, 
Basingstoke, Hampshire 
Magnetic stirrer 
Fisher Scientific U.K. 
Loughborough, Leicestershire 
Micropipettes 100-1000L Gilson, France 
Malvern Mastersizer® X 
Malvern Instruments Limited, 
Worcestershire 
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Thoma welled slides and cover slips 
Weber Scientific International Limited, 
Teddington, Middlesex 
Glassware 
Fisher Scientific U.K. 
Loughborough, Leicestershire 
 
 
3.3 EXPERIMENTAL DESIGN 
 
3.3.1 Preparation of the Kabiven® Peripheral Bag Samples 
 
Two different mixtures were prepared by mixing a reconstituted Kabiven® Peripheral 
Bag 900 kcal/5gN firstly with Additrace®, Vitlipid® N and Solvitio® N, and secondly 
with Vitlipid® N and Solvitio® N without Additrace®. Manipulation with each bag was 
carried out in the laminar flow workstation, which was cleaned by 70% isopropyl 
alcohol. It provides a protected work area without microbial contamination. 
 
3.3.1.1 Bags with Additrace® Concentrate (Bags A) 
 
10 ml of Additrace® concentrate was syringed into a reconstituted bag via a 10ml 
syringe. Then another 10ml syringe was filled with 10 ml of Vitlipid® N emulsion, and 
one vial of Solvitio® N was reconstituted by this emulsion. This mixture was 
altogether put into the same syringe and added to the bag. The volume of the bag 
was carefully mixed up. In all, three bags were prepared this way. From each bag, 20 
ml of the mixture was taken away into the Hach tubes (25 ml) for chemical and 
physical assays at time zero. A 1ml sample was taken from this tube via a plastic 
pipette into autosampler vial for HPLC assay. Two vials were prepared this way. The 
rest of the sample in Hach tube served for physical tests. Bags were stored in the 
refrigerator until other stability tests were carried out at a different time.  
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Figure 3.1: Hach Tube Figure 3.2: Kabiven® Peripheral Bags A and B 
               
 
 
3.3.1.2 Bags without Additrace® Concentrate (Bags B) 
 
A mixture of the Vitlipid N and Solvitio N was syringed into a reconstituted bag via 
a 10ml syringe. Preparation of this mixture was the same as in previous paragraph. 
Additrace concentrate was not added. There were three bags prepared. From each 
bag 20 ml of the mixture was taken away and put into the Hach tubes (25 ml) for 
chemical and physical assays at time zero. A 1ml sample was taken from this tube 
via a plastic pipette into autosampler vial for HPLC assay. Two vials were prepared 
this way. The rest of the sample in Hach tube served for physical tests. Bags were 
stored in the refrigerator until another stability tests were carried out at a different 
time. 
 
 
 
 
 
 
 
 
 
 
 
- 58 - 
 
Figure 3.3: Additrace®, Vitlipid® N, Solvitio® N 
 
 
 
3.3.1.3 The Sampling Technique of the Kabiven® Peripheral Bags 
 
Chemical assays by HPLC and physical tests were carried out after: 
 7 days storage in a refrigerator followed 24 h and 48 h storage at ambient 
temperature and protected from day-light. 
 14 days storage in a refrigerator followed 24 h and 48 h storage at ambient 
temperature and protected from day-light. 
 29 days storage in a refrigerator followed 24 h and 48 h storage at ambient 
temperature and protected from day-light. 
 
 
3.4 PHYSICAL ANALYSIS 
 
The following analyses were carried out. Emulsions were visually checked with the 
naked eye as well as by light microscopy. The lipid particle size was measured by 
Malvern Mastersizer® X, and the osmolality was measured with The Advanced 
Osmometer. The pH of the emulsions was determined by using Orion pH meter. 
 
 
 
  
- 59 - 
 
3.5 INSTRUMENTS USED FOR PHYSICAL TESTS 
 
Instruments which were used are listed in Table 3.4. 
 
3.5.1 Light Microscope 
 
Microscopy was used for observation of lipid particle size in tested emulsion 
samples. A pre-calibrated light microscope (Olympus® BH–2) was used. 
 
Figure 3.4: Olympus® BH-2 
 
        
 
 
One drop of the emulsion was placed in the centre of a Thoma-welled counting 
chamber slide of a height of 0.2 mm, and gridlines of a total of 256 squares. A 1ml 
syringe was used and the sample was then covered with a glass cover slip. It is 
important to avoid creating air bubbles, which may cause a problem, because their 
appearance is similar to lipid globules.  
The samples were examined at 100-time magnification. One unit gridline of the scale 
is equivalent to 10 m in size. The biggest particle size, the amount of particles 
bigger than 10 m and particles between 7.5-10 m, were recorded. The particles 
that were visible outside of the grid were not included. 
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3.5.2 The Mastersizer® X Laser Diffraction Particle Size Analyser 
 
The Malvern Mastersizer particle size analyzer uses the laser diffraction technique 
which is based on the analysis of the diffraction pattern produced when particles are 
exposed to a beam of monochromatic light. 
 
 
Figure 3.5: Laser Diffraction System 
 
 
 A representative sample, dispersed at an adequate concentration in a suitable liquid 
or gas, is passed through a beam of monochromatic light, usually a laser. The light 
scattered by the particles at various angles is measured by a multi-element detector. 
Numerical values representing the scattering pattern are then recorded for 
subsequent analysis. These scattering pattern values are then transformed, using an 
appropriate optical model and mathematical procedure, to yield the proportion of total 
volume to a discrete number of size classes, forming a volumetric particle-size 
distribution.  
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Figure 3.6: Laser Diffraction Instrument 
 
 
 
 
 
The particles can enter the laser beam in 2 positions. In the conventional case the 
particles enter the parallel beam before the collecting lens and within its working 
distance. In so-called reversed Fourier optics the particles enter behind the collecting 
lens and thus, in a converging beam. The advantage of the conventional set-up is 
that a reasonable path length for the sample is allowed within the working distance of 
the lens. The second set-up allows only small path lengths but enables measurement 
of scattered light at larger angles, which is useful when submicron particles are 
present. Traditionally, the measurement of particle size using laser diffraction has 
been limited to particles in the range of approximately 0.1 µm to 3 mm38. 
 
The size of the lipid globules is measured by passing the laser beam through the 
emulsion samples dispersed in ultrapure deionised water. The sampler was filled with 
ultrapure deionised water and stirred at a constant flow rate. Firstly the background 
was measured and then the sample was added. It was necessary to add the sample 
slowly. The amount of sample required was adjusted to an obscuration value 
between 19% - 21%. Initial tests carried out with Kabiven® Peripheral Bag emulsions 
required to add about 15 drops of this emulsion to obtain this obscuration 
concentration. The particle size data was analysed using the Malvern Mastersizer® 
software version 2.19. 
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3.5.3 The pH Meter 
 
The pH is a number which represents conventionally the hydrogen ion concentration 
of an aqueous solution39. Orion® Model 420A pH meter was used for measuring my 
samples. This measuring system comprises of two electrodes, the sensitive glass 
electrode and a combined reference electrode.  
 
 
Figure 3.7: Orion® pH meter Model 420A 
 
 
 
The glass electrode consists of a glass tube with a sealed membrane of glass at its 
base. The membrane glass bulb is filled with buffer into which a silver wire (Ag) 
coated with silver chloride (AgCl) is placed. When a pH glass electrode comes in 
contact with an aqueous measuring solution a gel layer develops on the pH-sensitive 
glass membrane and inside of this membrane as well. The H ions either diffuse out 
of the layer or into the gel layer, depending on the pH value of the measured solution. 
The total membrane potential is a result of the difference between the inner and outer 
charge. In the combination electrode the glass electrode is concentrically surrounded 
by the reference electrolyte40. 
 
The pH meter was calibrated before use with pH 7 phosphate buffer (Fisher Scientific 
U.K., Loughborough, Leicestershire). The glass electrode was inserted into the 
sample using the holder. It is necessary to wash the glass electrode with distilled 
water between measuring each sample to prevent contamination.  
 
 
- 63 - 
 
3.5.4 Osmometer 
 
Osmometers are devices designed for extremely precise measurement of the 
osmotic concentration of body fluids. The Advanced Model 3D3 Osmometer 
determines solute concentration by the extremely precise freezing point method. 
 
Osmometer is the apparatus for measuring osmolality. The unit of osmolality is 
osmole per kilogram (osmol/kg), but the submultiple milliosmole per kilogram 
(mosmol/kg) is usually used. Osmolality m is determined by measurement of the 
depression of freezing point. The following relationship exists between the osmolality 
and the depression of freezing point ΔT41:  
 
m = kgmosmol
T /1000
86.1
  
 
Figure 3.8: The Advanced Osmometer 
 
 
 
A pre-calibrated The Advanced Osmometer Model 3D3 was used.  The amount of 
250 l of the sample was given into sample tubes for in vitro diagnostic with Gilson 
micropipette. Osmolality was determined at each sample at time zero, after 29 days 
of storage in the refrigerator followed by 24 hours and 48 hours of storage at ambient 
temperature and under light protected conditions. 
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3.5.5 Laminar Flow Cabinet 
 
The horizontal laminar flow cabinet, Microflow, is fitted with high efficiency 
particulate air (HEPA) filter with 99.97% efficiency. The HEPA filter provides 
ultrafiltered air and allows a clean air work environment42. 
 
Throughout this project, all manipulation with the Kabiven Bags and preparation of 
the samples was performed in the laminar flow workstation. It provides aseptic work 
and it is necessary for avoidance of bacterial contamination. 
 
Figure 3.9: Laminar Flow Workstation 
 
 
 
 
 
 
3.6 CHEMICAL ASSAYS BY HPLC 
 
Liquid chromatography (LC) is a method of chromatographic separation based on the 
difference in the distribution of species between two non-miscible phases, in which 
the mobile phase is a liquid which percolates through a stationary phase contained in 
a column. The apparatus consists of a pumping system, an injector, a 
chromatographic column, a detector and a data acquisition system. The mobile 
phase is supplied from one or several reservoirs and flows through the column, 
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usually at a constant rate, and then through the detector43. HPLC is becoming a 
standard method in vitamin assay, especially for routine work44.  
 
 
3.6.1 HPLC Instrument System Used for Kabiven® Bags Analysis 
  
Thermo Spectra System P2000 gradient pump, UV detector 6000LP and Spectra 
Series AS1000 autosampler with 20l injection loop were used for the HPLC 
analysis. The data acquisition system software was called Chromquest 4.1. The 
column used was Varian® C18 stainless steel column, 150 mm × 3 mm ID, 5 µm 
particle size, fitted with a ChromStep C18 stainless steel guard column, 10 mm  2 
mm ID.  
 
3.6.2 Preparation of Phosphate Buffer Used for Kabiven® Bags Analysis 
 
The mobile phase used consists of phosphate buffer and methanol. Fresh solution of 
0.05M phosphate buffer pH 7 was prepared by dissolving 11.41 g 0.05M 
K2HPO4.3H2O in ultrafiltered deionised water. This solution was put into a 1000ml 
volumetric flask and filled with ultrafiltered deionised water. Amount of weighed 
K2HPO4.3H2O (formula mass FM= 228.22) was counted via the following figure: 
0.05M  228.22 = 11.41 g ( 0.05 g). The solution was put in a beaker, stirred with a 
magnetic stirrer and pH of this solution was measured. pH was adjusted to pH 7  
0.05 units by using orthophosphoric acid. Finally the buffer was filtered under 
vacuum through a 0.2 m polyamide filter. 
 
 
3.7 STATISTICAL ANALYSIS 
 
Microsoft Excel 2003 software for Windows was used for data analysis. All results 
throughout the project were expressed as the mean  standard deviation (sd) from 
triplicate samples.  
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CHAPTER FOUR: RESULTS AND DISCUSSION 
 
4.1 HPLC ANALYSIS OF KABIVEN PERIPHERAL BAGS 
 
Firstly it was necessary to develop an optimal method for vitamin assay by HPLC. 
The initial step was reading the PhD. thesis of Said42 paragraph 2.3: Chemical 
Assays by HPLC, whose project was similar to the one discussed in this diploma 
thesis. Previously published literature about vitamin assays by HPLC was consulted 
as well.  
 
A similar column and HPLC system, like Said42 used, was employed. Ultraviolet (UV) 
detection for the vitamins was recommended. The maximum absorbance for the 
water-soluble vitamins was found to be in ranges of 200-220 nm and 250-280 nm. 
The wavelength between 250-280 nm was preferred because most interference will 
absorb much less above 240 nm. Therefore, the methods that used UV detection 
between 250 - 280 nm were carried out42. 
 
The separation method from Said42 thesis was adapted for the water-soluble 
vitamins, which used a C18 column on gradient run, UV detection 265 nm and using 
phosphate buffer 0.05M pH 7 and methanol as the mobile phase.  
 
For the fat-soluble vitamins, the UV absorbance found was 292 nm for vitamin E and 
325 nm for vitamin A. Therefore methods that use two different wavelengths were 
carried out42. According to Said42 results, using the stability-indicating method 
described helps determine two vitamins, namely Vitamin A and Vitamin E. The other 
fat-soluble vitamins were omitted in this thesis. Methanol was used as the mobile 
phase.  
 
Following sections describe optimization of method for determination of vitamins in 
mixture Kabiven® Peripheral Bag with Solvitio® N solution, using given method for 
stability tests of tested samples, and HPLC instrument system. 
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4.1.1 Determination of Optimal Method for Water-soluble Vitamins 
 
For finding the optimal separating method, it was essential to change retention time 
of vitamins, because they were covered mono-acid peaks in the mixture of Bag with 
Solvitio®-Vitlipid® emulsion. Four samples were prepared. First was the clear 
reconstituted Kabiven® Peripheral Bag sample, according to which we identified 
mono-acid peaks. Second sample was Solvitio® N vial reconstituted with 10 ml of 
distilled water, and syringed into Kabiven® Bag. Another sample analysed was 
Solvitio® N solution, prepared from Solvitio® N vial reconstituted with 10 ml of 
distilled water and diluted 10 times with distilled water into 100ml volumetric flask. 
This sample served as standard for determination of vitamin peaks and evaluation of 
their retention times. The last sample was prepared from 10 time diluted Solvitio® N 
solution. 330 µl of this solution was put into 10ml volumetric flask and filled with 
distilled water to 10ml volume. Several different methods with various gradient runs 
were investigated. Different types of columns were employed. For a couple of 
samples acetonitrile with phosphate buffer pH 7 was used as a mobile phase. 
However this mobile phase seemed to be strong and moving the peaks was not 
optimal. When the optimal method was developed, Kabiven® Peripheral Bag 
samples could be analysed. 
  
4.1.2 HPLC Analysis for Water-soluble Vitamins Assay 
 
Solvitio® N Adult is an injectable multivitamin, in the form of a yellow powder for 
reconstitution42. 
 
All samples were analysed at ambient temperature, a reversed phase HPLC analysis 
with a gradient elution method was employed. Methanol and phosphate buffer 0.05M 
pH 7 was used as the mobile phase. The following gradient run was used:  
 1% methanol from 0 to 5 minutes, 
 1% - 30% methanol from 5 to15 minutes, 
 30% methanol from 15 to 20 minutes, 
 30% - 1% methanol from 20 to 20.1 minutes, 
 1% methanol from 20.1 to 25 minutes 
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Table 4.1: Gradient Run for Water-soluble Vitamins Assays 
 
Time (minutes) Buffer pH 7 MeOH 
 A% B% 
0 99 1 
5 99 1 
15 70 30 
20 70 30 
20.1 99 1 
25 99 1 
 
20 l sample was injected via autosampler. The flow rate was set 1 ml/min with UV 
detection 265 nm. 
  
4.1.3 Results and Discussion for Water-soluble Vitamins 
  
The chromatogram of Solvitio N standard solution is shown at Figure 4.1. Peaks of 
the Solvitio N solution were identified according to Said’s42 results and compared to 
chromatograms of Solvitio N solution in her thesis. Resulting retention times of 
Said’s42 chromatogram peaks slightly differ from the ones recorded in this research. 
This is because a different gradient run was used. The chromatogram peaks with the 
approximate retention times identified in Said 42 assays were:  
Ascorbic acid  rt. 0.76 minutes 
Pyridoxine hydrochloride rt. 3.70 minutes 
Nicotinamide rt. 4.80 minutes  
Thiamine hydrochloride rt. 6.30 minutes 
Folic acid rt. 11.10 minutes 
Riboflavin sodium phosphate rt. 12.40; 14.90; 16.90; 17.30; 20.50 minutes 
Pantothenic acid rt. 22.47 minutes 
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Figure 4.1: Chromatogram of Solvitio N Standard Solution 
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The chromatogram peaks with retention times, identified using my method were:  
Ascorbic acid rt. 0.67 minutes 
Pyridoxine hydrochloride rt. 3.46 minutes   
Nicotinamide rt. 4.82 minutes 
Thiamine hydrochloride rt. 5.54 minutes 
Folic acid rt. 10.23 minutes 
Riboflavin sodium phosphate rt. 14.61 minutes 
Pantothenic acid rt. 19.09 minutes 
 
 
Five peaks for riboflavin sodium phosphate were identified according to Said’s42 
results, which may be the isomers of riboflavin phosphate, riboflavin diphosphate and 
free riboflavin. The highest peak identified at about 14.61 minutes was used for 
analysis. Ascorbic acid was eluted very early in the gradient run, in less than one 
minute. The peak for cyanocobalamin was also identified, but its concentration in the 
multivitamin solution was too minute and the peak was hardly noticeable. The biotin 
peak could not be identified in this gradient run, and the peak for pantothenic acid 
was detected after 20 minutes of the gradient run. In Said’s42 thesis the peaks of 
degraded products were identified, mostly at retention times of less than 2 minutes. 
Therefore it was decided that this method was not suitable for analysing the ascorbic 
acid, because the peaks of the degraded products would interfere with the ascorbic 
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acid peak. Another degraded product peaks were detected after 20 minutes, 
therefore making this assay unsuitable for the analysis of pantothenic acid.  
 
Five vitamins were found to be suitable for assay by this method, which are 
pyridoxine, nicotinamide, thiamine, folic acid and riboflavin sodium phosphate42. On 
the other hand, only two water-soluble vitamins were possible to analyse at different 
times in the Kabiven® Bags, which are pyridoxine and riboflavin sodium phosphate 
(Figure 4.2). It was not possible to analyse other water-soluble vitamins, because 
they were covered by mono-acids peaks. It was not possible to shift every vitamin 
peak from mono-acid peaks. 
 
 
Figure 4.2: Chromatogram of Kabiven Bag with Vitamins - Detection of Water-
soluble Vitamins. Separation of Pyridoxine (rt. 3.96 minutes), and Riboflavin Sodium 
Phosphate (rt. 15.22 minutes) 
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4.1.3.1 Results for Water-soluble Vitamins in Kabiven® Bags A 
 
Amount of vitamin B6 was not less than 90 % during the storage period. Around 91 
% of the vitamin left after 7 days storage in the refrigerator followed two days storage 
at ambient temperature. After 14 days storage almost 95 % of the vitamin left and at 
the day 29+1 there was over 97 % of the vitamin (see Table 4.2). Amount of vitamin 
B2 was not less than 92 % of it’s initial amount. There were detected also values 
over 100 % of the initial amount of the vitamins. It might be caused by measure error. 
Degradation of these vitamins is not rapid and their losses are insignificant under 
assayed storage conditions. All results are expressed via graphs (see Figures 4.3, 
4.4 and 4.5) and Table 4.2. 
 
Table 4.2: Peak Area and RSD of WSV in Bags A throughout the Investigation 
 
vitamin B6   B2   
day peak area (%) RSD peak area (%) RSD 
0 100 0,54 100 0,60 
7 91,3 1,48 102,9 0,60 
7+1 90,5 0,23 96,5 2,20 
7+2 91,5 2,02 103,4 2,58 
  B6   B2   
day peak area (%) RSD peak area (%) RSD 
0 100 1,29 100 0,68 
14 94,5 0,71 94,8 11,3 
14+1 101,8 0,07 134,7 5,32 
14+2 106,4 1,05 99,8 5,45 
  B6   B2   
day peak area (%) RSD peak area (%) RSD 
0 100 6,71 100 13,5 
29 100,9 3,79 92,7 4,16 
29+1 97,8 1,59 95,9 5,82 
29+2 111,2 0,59 93,5 5,19 
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Figure 4.3: Peak Area for WSV in Kabiven® Bag A after 7 Days Storage in the Fridge 
 
 
 
 
Figure 4.4: Peak Area for WSV in Kabiven® Bag A after 14 Days Storage in the 
Fridge 
 
 
 
 
 
 
 
 
- 74 - 
 
Figure 4.5: Peak Area for WSV in Kabiven® Bag A after 29 Days Storage in the 
Fridge 
 
 
 
4.1.3.2 Results for Water-soluble Vitamins in Kabiven® Bags B 
 
Amount of vitamin B6 was not less than 93 % of its initial amount during storage 
period. Losses of this vitamin are insignificant when the bags are light-protected. On 
the other hand losses of vitamin B2 were more significant than vitamin B6 losses. 
Only 81 % of the vitamin left after 14 days storage in the refrigerator (see table 4.3). 
The results having values over 100 % of their initial amount are probably influenced 
by measure error. Some results may be influenced by changing ambient temperature 
during stability studies, exactly the sensitivity of the detector may be influenced by 
big temperature difference between single assays. All results are expressed in the 
graphs (see Figures 4.6, 4.7 and 4.8) and in the Table 4.3. 
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Table 4.3: Peak Area and RSD of WSV in Bags B throughout the Investigation 
 
  B6   B2   
day peak area (%) RSD peak area (%) RSD 
0 100 0,36 100 1,64 
7 93,4 0,11 97,9 1,38 
7+1 93,3 0,43 93,8 0,93 
7+2         
          
  B6   B2   
day peak area (%) RSD peak area (%) RSD 
0 100 2,97 100 2,43 
14 96,5 0,27 81,9 2,05 
14+1 95,6 1,64 145,3 2,03 
14+2 97,8 1,28 88,4 1,24 
          
  B6   B2   
day peak area (%) RSD peak area (%) RSD 
0 100 3,90 100 2,88 
29 93,2 0,88 98,7 1,09 
29+1 98,2 0,08 102,7 2,56 
29+2 98,2 0,29 103,0 4,26 
 
 
Figure 4.6: Peak Area for WSV in Kabiven® Bag B after 7 Days Storage in the Fridge 
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Figure 4.7: Peak Area for WSV in Kabiven® Bag B after 14 Days Storage in the 
Fridge 
 
 
Figure 4.8: Peak Area for WSV in Kabiven® Bag B after 29 Days Storage in the 
Fridge 
 
 
4.1.3.3 Discussion for Water-soluble Vitamins in Kabiven® Bags 
 
Stability of vitamins is discussed in previous paragraph 2.6 Vitamins. Riboflavin is 
degraded rapidly when exposed to daylight11. Previous HPLC results have shown 
that degradation of riboflavin is not rapid when the bags are light protected. 
Commencing infusion in the evening makes sure us that the patient receives greater 
amounts of this vitamin. The results also have shown that degradation of riboflavin 
was not influenced by presence of trace elements, because there was not any bigger 
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difference between values in Kabiven® Bags A and B. Pyridoxine is also light-
sensitive also degradation is far less than is observed with riboflavin11. Almost no 
losses of pyridoxine were detected in light-protected bags throughout the 
investigation. There was not any influence of TE to pyridoxine stability in Kabiven® 
Bags as the results showed. Therefore both discussed vitamins should be deliver 
and stored light-protected and then they should be stable and their losses should be 
only very small. 
 
4.1.4 HPLC Analysis for Fat-soluble Vitamins Assay 
 
A reversed phase HPLC analysis using two different UV detections in a single run 
was employed. The mobile phase was methanol HPLC grade, set at a flow rate of 
1.5 ml/min. Two wavelengths were used, 292 nm for the detection of vitamin E and 
325 nm for the detection of vitamin A. A 20 µl sample was injected via the 
autosampler42.  
 
4.1.5 Results and Discussion for Fat-soluble Vitamins Assay 
 
Peaks for vitamin A and vitamin E were identified by comparing chromatograms of 
fat-soluble sample emulsion from Said42 thesis with chromatograms obtained from 
analysis of 10 ml of Vitlipid® N Adult injection diluted in a 100ml volumetric flask with 
ultrafiltered deionised water. Peaks were identified at 2.65 minutes for vitamin E 
(Figure 4.9) and at 8.53 minutes for vitamin A (Figure 4.10).  Peaks for vitamin K and 
vitamin D were observed too, but according to Said42 results these two vitamins are 
unsuitable for analyses by this stability-indicating method. Vitamin K peak was too 
small with lack of sensitivity and from the calibration curve of vitamin D less linearity 
and therefore less precision was found. 
For the fat-soluble Vitlipid N Adult vitamin assay the stability-indicating method 
described was able to determine two vitamins, namely Vitamin A and Vitamin E in 
single run42.  
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Figure 4.9: Chromatogram of Vitlipid N Injection - Detection of Vitamin E (rt. 2.65 
minutes) 
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Figure 4.10: Chromatogram of Vitlipid N Injection- Detection of Vitamin A (rt. 8.53 
minutes) 
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Figure 4.11: Chromatogram of Kabiven Bag with Vitamins- Detection of Vitamin E 
(rt. 2.35 minutes) 
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Figure 4.12: Chromatogram of Kabiven Bag with Vitamins- Detection of Vitamin A 
(rt. 8.40 minutes) 
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4.1.5.1 Results of HPLC for Fat-soluble Vitamins in Kabiven® Bags A 
 
Amount of vitamin A was found about 65% of its initial amount throughout storage 
period. Only 65 % left after 29 days storage in the refrigerator followed two days 
storage at ambient temperature. Losses after storage in the refrigerator were smaller 
than losses after storage at ambient temperature (see Table 4.4). Some values were 
over 100 %, it was probably caused by measure error. Degradation of vitamin A was 
biggest after 29 days storage in the fridge followed two days storage at ambient 
temperature. Degradation of Vitamin E was massive, especially when the bags were 
stored at ambient temperature. If they were stored in the refrigerator, the losses were 
not so significant (see table 4.4). All results are expressed in the following graphs 
(see Figures 4.13, 4.14 and 4.15) and in the Table 4.4. 
 
Table 4.4: Peak Area and RSD of FSV in Bags A throughout the Investigation 
 
vitamin A   E   
day peak area (%) RSD peak area (%) RSD 
0 100 7,82 100 1,94 
7 116,18 0,77 108,18 10,7 
7+1 98,18 13,6 94,45 3,13 
7+2 96,10 6,99 46,84 22,6 
  A   E   
day peak area (%) RSD peak area (%) RSD 
0 100 7,74 100 0,43 
14 109,86 6,46 101,29 3,24 
14+1 94,76 1,82 84,90 6,80 
14+2 91,30 15,9 72,17 2,85 
  A   E   
day peak area (%) RSD peak area (%) RSD 
0 100 4,63 100 2,86 
29 84,49 1,56 81,75 4,16 
29+1 81,19 3,14 56,78 7,58 
29+2 65,45 1,90 27,22 4,93 
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Figure 4.13: Peak Area for FSV in Kabiven® Bag A after 7 Days Storage in the 
Fridge 
 
 
 
 
 
Figure 4.14: Peak Area for FSV in Kabiven® Bag A after 14 Days Storage in the 
Fridge 
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Figure 4.15: Peak Area for FSV in Kabiven® Bag A after 29 Days Storage in the 
Fridge 
 
¨ 
 
4.1.5.2 Results of HPLC for Fat-soluble Vitamins in Kabiven® Bags B 
 
Amount of vitamin A was found about 83 % of its initial amount throughout storage 
period. Some values over 100 % were probably influenced by measure error. 
Especially the results at days 14, 14+1 and 14+2 were influenced by detector 
sensitivity, because in these days the ambient temperature was much higher than 
during other single assays (see Table 4.5). Degradation of vitamin A was bigger if the 
bags were stored at ambient temperature. Vitamin E losses were not as rapid as 
losses in the bags A. Amount of vitamin E was not less than 66 % at day 7+1. Other 
values showed that amount of degraded vitamin E is less 20 %. All results are 
showed in the graphs (see Figures 4.16, 4.17 and 4.18) and in the Table 4.5.  
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Table 4.5: Peak Area and RSD of FSV in Bags B throughout the Investigation 
 
  A   E   
day peak area (%) RSD peak area (%) RSD 
0 100 1,08 100 1,52 
7 101,18 0,31 81,18 11,9 
7+1 87,73 2,76 66,51 10,1 
7+2 83,13 5,12 95,60 7,03 
          
  A   E   
day peak area (%) RSD peak area (%) RSD 
0 100 4,11 100 0,70 
14 116,99 1,05 106,82 1,50 
14+1 108,96 1,29 93,65 0,40 
14+2 115,42 2,72 102,72 1,04 
          
  A   E   
day peak area (%) RSD peak area (%) RSD 
0 100 3,61 100 10,1 
29 100,57 3,73 97,02 5,16 
29+1 94,60 1,88 92,53 1,25 
29+2 97,41 2,66 92,77 1,47 
 
 
Figure 4.16: Peak Area for FSV in Kabiven® Bag B after 7 Days Storage in the 
Fridge 
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Figure 4.17: Peak Area for FSV in Kabiven® Bag B after 14 Days Storage in the 
Fridge 
 
 
 
Figure 4.18: Peak Area for FSV in Kabiven® Bag B after 29 Days Storage in the 
Fridge 
 
 
4.1.5.3 Discussion for Fat-soluble Vitamins in Kabiven® Bags 
 
Stability of vitamins A and E was discussed in previous paragraph 2.6 Vitamins. 
Retinol is the most light-sensitive of the vitamins and is known to be rapidly broken 
down by exposure to UV light11. Kabiven® Bags were light-protected throughout the 
project, therefore degradation was not rapid. Losses of vitamin A were less when the 
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bags were stored in the refrigerator. The presence of amino acids and fat emulsion in 
the bag affords considerable protection of retinol11. This might be the reason why 
losses of retinol were reduced. Stability of retinol was not influenced by presence of 
TE as obtained results showed. On the other hand, degradation of vitamin E was not 
as rapid in the Bags B as in the Bags A. It was probably caused by presence of TE. 
Harraki2 reported that there is an important interaction between Se and vitamin C and 
E. Vitamin E degrades very fast if the Bags are stored out of refrigerator and if the TE 
are presented. There is also possibility of sorption vitamin E to the bag as Allwood11 
reported.  
 
 
4.2 RESULTS AND DISCUSSION OF pH FOR KABIVEN® BAGS 
 
4.2.1 pH Results of Kabiven® Bags A and B 
 
a) The measured pH in the Bags A was in range between 5.44 at day seven plus one 
and 6.00 at day twenty nine. Only one value differs from the initial value of pH in 
more than 0.5 units. This value 6.00 was measured after 29 days storage in the 
fridge (see Table 4.6). The changes of pH after 24 and 48 hours storage at ambient 
temperature are quite small. The biggest differece is 0.36 units and it is between day 
seven and day seven plus two. The other changes are insignificant because they are 
not to enormous. The graphical results are expressed in Figures 4.19, 4.20 and 4.21 
in differen time. 
 
b)  The measured pH in the Bags B was in range between 5.38 at day seven plus 
two and 5.97 at day twenty nine plus one (see Table 4.6). Except of the difference 
0.43 units between pH at day seven and pH at day seven plus one, all changes of pH 
are quite small and all values of pH are less than 0.5 units. The graphical results are 
expressed in Figures 4.19, 4.20 and 4.21. 
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Table 4.6: pH of Kabiven® Bags throughout the Investigation 
 
pH/day 0 7 7+1 7+2 14 14+1 14+2 29 29+1 29+2 
Bag A 5.49 5.45 5.44 5.85 5.88 5.86 5.77 6.00 5.88 5.84 
Bag B 5.55 5.53 5.96 5.38 5.92 5.92 5.88 5.97 5.94 5.91 
 
Figure 4.19: pH of Kabiven® Bags A and B after 7 Days Storage in the Fridge 
 
 
 
 
 
Figure 4.20: pH of Kabiven® Bags A and B after 14 Days Storage in the Fridge 
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Figure 4.21: pH of Kabiven® Bags A and B after 29 Days Storage in the Fridge 
 
 
 
 
4.2.2 Discussion 
 
Allwood11 reported that pH changes can lead to significant loss of stability or to 
precipitation. That is the reason why observation of pH is important. Changes of pH 
which are less than 0.5 units are negligible. Only changes of pH bigger than 0.5 units 
may cause dangerous precipitation. According to the results pH changes were in 
norm, except one value which differed from initial pH value in more than 0.5 units. 
This change was observed after 29 days storage in refrigerator in Bag A. Addition TE 
into the Bag showed, that probably has not any influence to pH changes in time. 
Therefore, investigated admixtures are suitable for intravenous delivery. The most 
stable are admixtures stored for 7 days in refrigerator and then followed one day 
storage at ambient temperature. After longer storage period (14 or 29 days) stability 
of admixtures is decreasing.  
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4.3 Results and Discussion of Kabiven® Bags Microscopy 
 
4.3.1 Microscopy Results of Kabiven® Bag A 
 
Many enlarged particles were seen in Kabiven® admixtures A. The biggest lipid 
globule of 25 µm was observed at day twenty-nine plus two (see Table 4.11). At all 
time points there were globules bigger than 10 µm except day zero. Particles in 
range 7.5 and 10 µm are showed in Table 4.7. All other lipid globules were 5 µm or 
smaller at all time points.   
 
Table 4.7: Results of Microscopy of Kabiven® Bags A 
 
Bag A       
day 
biggest particle size 
(m) 
amount of particles 
10m
particle size 7.5-10 
m 
0 10 0 4 
        
7 10   5 
7+1 12,5 1 5 
7+2 12,5 1 4 
        
        
14 10   3 
14+1 20 4 4 
14+2 20 2 5 
        
29 20 1 6 
29+1 20 3 6 
29+2 25 4 6 
 
4.3.2 Microscopy Results of Kabiven® Bag B 
 
Many enlarged particles were seen in Kabiven® admixtures B. The biggest lipid 
globules of 25 µm were observed at days fourteen plus two and twenty-nine plus two 
(see Table 4.8). One particle bigger than 10 µm was observed at day seven plus two, 
two particles at day fourteen plus two, three particles were observed at day seven 
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plus one and four particles at day twenty-nine plus two. Partcles in range 7.5 and 10 
µm are showed in Table 4.8. All other lipid globules were 5 µm or smaller at all time 
points.   
 
Table 4.8: Results of Microscopy of Kabiven® Bags B 
 
Bag B       
day 
biggest particle size 
(m) 
amount of particles 
10m
particle size 7.5-10 
m 
0 10 0 5 
        
7 10  0 4 
7+1 12,5 3 4 
7+2 12,5 1 4 
        
        
14 10  0 3 
14+1 10  0 5 
14+2 25 2 4 
        
29 10  0 5 
29+1 10  0 6 
29+2 25 4 7 
 
 
4.3.3 Discussion 
 
Potential interactions of combined TPN mixtures were discussed in paragraph 2.9. 
Allwood11 reported that precipitation may be a result of temperature changes, pH 
changes or poor mixing. The results showed that most stable admixtures are those 
stored for seven days in refrigerator. If they are stored for more than 7 days they 
become unstable because of higher amount of enlarged lipid globules. Bags without 
TE contain less enlarged particles, especially after longer storage period (14 and 29 
days), it means that stability of admixtures is decreasing when TE are presented and 
storage period is prolonged.  
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4.4 Results and Discussion of Laser Diffraction of Kabiven® Bags 
 
4.4.1 Kabiven® Bag A Laser Diffraction Results 
 
Very few enlarged lipid droplets were detected in the Kabiven® Bag A containing 
samples. Many samples presented a maximum particle size of just 4.3 µm. Particles 
of 8.04 µm were observed at day seven plus two, exactly 0.12 volume percentage. 
Enlarged lipid particles were observed at day twenty-nine plus one  and twenty-nine 
plus two as well, it means particles of 12.21 µm were contained in 0.12 volume 
percentage at both time points (see Figure 4.23). All other lipid globules were 4.3 µm 
or smaller at all time points.  
 
 
Figure 4.22: Particle Size Distribution of Globules in Lipid Admixtures (Bag A-Day 
Zero) 
 
 
 
 
 
 
 
 
 
- 91 - 
 
Figure 4.23: Particle Size Distribution of Globules in Lipid Admixtures (Bag A-Day 
twenty-nine plus one) 
 
 
 
 
4.4.2 Kabiven® Bag B Laser Diffraction Results 
 
Very few lipid droplets greater than 4.3 µm were detected in the Kabiven® Bag B 
containing samples. Many samples presented a maximum particle size of 3.49 µm. 
There were detected couple enlareged lipid particles of 6.52 µm in 0.178 volume 
percentage and 12.21 µm in 0.148 volume percentage at day twenty-nine plus two 
(see Figure 4.25). All other lipid globules were 4.3 µm or smaller at all time ponits 
(see Figure 4.24). 
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Figure 4.24: Particle Size Distribution of Globules in Lipid Admixtures (Bag B-Day 
Zero) 
 
 
 
Figure 4.25: Particle Size Distribution of Globules in Lipid Admixtures (Bag B-Day 
twenty-nine plus two) 
 
 
 
4.4.3 Discussion 
 
Intravenously administered fat droplets exceeding 5 µm in diameter are believed to 
cause adverse reactions, in particular emboli of the lungs. There was found a 
relationship between particle size and toxicity. The toxicity increases with higher 
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average particle size and wider particle size distribution. Many authors take 5 µm as 
the upper limit, since larger particles pose a risck of lung embolism45. 
 
Very few lipid globules in Kabiven® Bag A samples were enlarged. Emulsions in 
which >0.4 % of the fat particles are above 5 µm, are likely to become unstable45. In 
my trials the volume of droplets bigger than 5 µm was not so big, exactly was less 
than 0.4 %. Larger lipid droplets were presented after 29 days storage in the 
refrigerator and then after two days storage at ambient temperature. Concerning the 
lipid globules size this admixture  could be used for intravenous delivery after seven 
days and fourteen days storage in the refrigerator. There is bigger probability 
adverse reaction after delivery admixture after twenty-nine days storage in the fridge 
followed two days storage at ambient temperature. On the other hand lipid particles 
with diameter even greater than 7.5 µm can deform and pass through the pulmonary 
vasculature without difficulty45. 
 
 
4.5 Results of Osmolality of Kabiven® Bags 
 
Osmolality was measured at day zero, day twenty-nine, day twenty-nine plus one 
and day twenty-nine plus two. The osmolality values are expressed in Table 4.14.   
 
Table 4.9: Osmolality of Kabiven® Bags 
 
 Bag A Bag B 
day Osmolality (mOsm/kg) Osmolality (mOsm/kg) 
0 818 795 
29 799 800 
29+1 809 798 
29+2 817 794 
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CHAPTER FIVE: CONCLUSIONS 
 
All discussed vitamins are light-sensitive, especially vitamin A and riboflavin. All 
analysed bags were light protected throughout the thesis therefore degradation was 
not as rapid as in case if they were not light-protected. Loses of all vitamins were 
also less when the bags were stored in a refrigerator. Degradation was faster when 
the bags were stored at ambient temperature. Presence of TE caused rapid 
degradation of vitamin E, on the other hand stability of riboflavin, vitamin A and 
pyridoxine was not influenced by TE. Prolonged storage period caused less stability 
of all assayed bags, especially when TE were presented, because of enlarged lipid 
globules. It means that the most stable are these admixtures which are stored for 
seven days in a refrigerator. Pyridoxine was found the most stable among all 
analysed vitamins. Its losses were negligible even after 29 days storage or if trace 
elements were presented.  The least stable vitamin was found vitamin E, especially 
in a mixture with trace elements.  
All results could be summarize by following points: 
 All discussed vitamins are light-sensitive and day-light protection caused that 
losses of these vitamins were multiple less. 
 It was found that vitamin E is rapidly degraded when is in the mixture with 
trace elements. Degradation of vitamin E is not so significant when the mixture 
is trace elements free.  
 All vitamins are stable when they are stored in a refrigerator for first seven 
days. If they are stored at ambient temperature, stability has decreasing 
tendency.  
 Vitamin A should not be stored more than 14 days in a refrigerator if trace 
elements are presented. Vitamin E should not be stored more than 7 days in a 
fridge if trace elements are presented. In these cases degradation of vitamins 
is rapid.  
 Pyridoxine is the most stable vitamin and its losses were negligible.  
 The most stable admixtures are those stored for seven days in refrigerator. If 
they are stored for more than 7 days they become unstable because of higher 
amount of enlarged lipid globules. Bags without TE contain less enlarged 
particles, especially after longer storage period (14 and 29 days), it means that 
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stability of admixtures is decreasing when TE are presented and storage 
period is prolonged.  
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SOUHRN 
 
Parenterální výživa se stala akceptovanou metodou pro prevenci a nápravu 
podvyživenosti u pacientů, u kterých nemůže být dostatečná výživa poskytnuta 
gastrointestinální cestou2. Směsi parenterální výživy se skládají z tuků, sacharidů, 
proteinů, vitamínů, stopových prvků, elektrolytů a tekutin. Vitamíny jsou považovány 
za nejméně stabilní složky v parenterálních směsích, a tudíž by měly být přidány 
bezprostředně před aplikací infuze.  
Cílem této diplomové práce bylo získat informace o stabilitě vitamínů ve 
směsích parenterální výživy v závislosti na odlišných skladovacích podmínkách a na 
době skladování. Konkrétně byla sledována stabilita vitamínů rozpustných ve vodě 
(B2, B6) i vitamínů rozpustných v tucích (A, E), které byly přidány do Kabiven® 
Peripheral vaku (viz. Tabulka 3.1) nejdříve se stopovými prvky a poté bez stopových 
prvků. Fyzikální a chemická analýza směsí byla provedena v následujících 
intervalech: 
 V čase přípravy směsi 
 Po sedmi dnech skladování v lednici následována 24 a 48 hodinami 
skladování při pokojové teplotě.   
 Po čtrnácti dnech skladování v lednici následována 24 a 48 hodinami 
skladování při pokojové teplotě. 
 Po dvaceti devíti dnech skladování v lednici následována 24 a 48 hodinami 
skladování při pokojové teplotě. 
 
Všechny infuzní vaky byly po celou dobu testování chráněny před denním světlem. 
 
Infuzní vaky byly připraveny dvěma různými způsoby:  
 První sada vaků (A) byla připravena smísením rekonstituovaného vaku 
Kabiven® Peripheral s Additrace® koncentrátem (viz. Kapitola 3.2) pomocí 
10ml injekční stříkačky. Solvitio® N prášek (viz. Kapitola 3.2) byl 
rekonstituován pomocí Vitlipid® N emulze (viz. Kapitola 3.2) 10ml stříkačkou a 
vzniklá emulze byla stejnou stříkačkou přidána do infuzního vaku A, který byl 
následně dobře promíchán. Tímto způsobem byly připraveny celkem tři infuzní 
vaky A. Z každého vaku bylo odebráno injekční stříkačkou 20 ml směsi, 
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přemístěno do Hach zkumavky (viz. Obr. 3.1) a připraveno k fyzikální analýze 
v čase přípravy směsi. 1 ml této směsi z každé zkumavky byl požit pro analýzu 
HPLC. Po odebrání vzorku byly vaky uskladněny v lednici, dokud nebyla 
provedena další analýza.  
 Druhá sada vaků (B) byla připravena obdobným způsobem jako sada A, ale 
bez přídavku Additrace® koncentrátu. Stopové prvky tudíž v těchto vacích 
chyběly. Bylo připraveno stejné množství vaků jako v předešlém odstavci, 
které byly následně analyzovány stejným způsobem jako vaky A.  
Manipulace se všemi vaky byla provedena v boxu s laminárním prouděním, aby se 
zabránilo mikrobiální kontaminaci. 
 
Fyzikální analýza zahrnovala následující metody: emulze byly zkontrolovány prostým 
okem a pomocí světelného mikroskopu. Velikost lipidových částic byla určena 
laserovou difrakcí prostřednictvím Malvern Mastersizer® X a osmolalita byla 
změřena pomocí The Advanced Osmometer. pH emulzí bylo změřeno pomocí 
Orion pH metru (viz. Tabulka 3.4). Chemická analýza byla provedena pomocí 
HPLC analýzy. Směs metanolu a 0.05M fosfátového pufru pH 7 jako mobilní fáze 
byla použita pro analýzu vitamínů B2 a B6 (viz. Kapitola 3.6). Jako mobilní fáze pro 
analýzu vitamínů A a E byl použit metanol (viz. Kapitola 4.1.4). 
 
Všechny analyzované vitamíny jsou citlivé na světlo, speciálně vitamín A a riboflavin. 
Proto byly všechny vaky, použité k analýze, chráněny před denním světlem a tudíž 
degradace vitamínů nebyla tak rozsáhlá jak by tomu bylo v opačném případě. 
Vitamínové ztráty byly menší, pokud infuzní vaky byly uloženy po dobu trvání 
stabilitních studií v lednici. Degradace byla rychlejší v případě uchovávání vaků při 
pokojové teplotě. Přítomnost stopových prvků ve směsi způsobila významnou 
degradaci vitamínu E, ale stabilita ostatních vitamínů jimi nebyla nijak významně 
ovlivněna (viz. Tabulka 4.4 a 4.5). Stabilita všech analyzovaných vaků klesala 
s prodlužováním doby skladování, obzvlášť v přítomnosti stopových prvků, kvůli 
přítomnosti zvětšených lipidových částic. Nejstabilnější byly tudíž ty směsi, které byly 
uchovávány maximálně po dobu sedmi dní za snížené teploty. Ze všech 
analyzovaných vitamínů byl pyridoxin shledán jako nejstabilnější. Jeho ztráty byly 
zanedbatelné dokonce i po 29 denním skladování nebo ve směsi se stopovými 
- 99 - 
 
prvky. Nejméně stabilním vitamínem byl vitamín E, zvlášť ve směsi se stopovými 
prvky. 
Všechny výsledky můžeme shrnout do několika bodů: 
 Všechny výše zmíněné vitamíny jsou citlivé na světlo, tudíž ochrana infuzí 
před denním světlem má za následek, že ztráty vitamínů jsou 
několikanásobně nižší.  
 Bylo zjištěno, že vitamín E rychle degraduje ve směsi se stopovými prvky. 
Jestliže je vitamín E ve směsi prosté stopových prvků, degradace není tak 
výrazná.  
 Všechny vitamíny byly stabilní po dobu prvních sedmi dní uskladnění v lednici. 
Pokud jsou uskladněny při pokojové teplotě, stabilita rychle klesá.  
 Vitamín A by neměl být skladován v lednici po dobu delší než 14 dní, pokud je 
ve směsi se stopovými prvky. Vitamín E by neměl být skladován v lednici více 
než 7 dní, pokud jsou přítomny stopové prvky. V těchto případech stabilita 
obou vitamínů rapidně klesá.  
 Pyridoxin je nejvíce stabilní vitamín a jeho ztráty byly zanedbatelné.  
 Nejvíce stabilní směsi se ukázaly ty, které byly uskladněny v lednici po dobu 7 
dnů. V případě delšího skladování se stávají méně stabilními, díky většímu 
množství zvětšených lipidových částic. Infuzní vaky bez přídavku stopových 
prvků obsahují mnohem méně zvětšených lipidových částic, obzvlášť po delší 
době skladování (14 a 29 dní). To znamená, že stabilita směsí klesá 
s přítomností stopových prvků a s prodlužující se dobou skladování.  
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ABSTRACT 
 
Parenteral Nutrition (PN) is an alternative method of providing nutritional support for 
patients via the intravenous route. Patients selected for PN are malnourished 
patients or patients who have the potential to become malnourished. PN admixtures 
consist of fats, carbohydrates, proteins, vitamins, trace elements, electrolytes and 
fluids. Vitamins are believed to be among the least stable ingredients in PN mixtures 
and should be added immediately before commencing infusion. The purpose of this 
thesis is to obtain information on stability of the vitamins in PN admixtures depending 
on different storage conditions and different time.  
 
Water-soluble vitamins and fat-soluble vitamins were investigated in the mixture of 
Kabiven® Bag (Fresenius Kabi) with Vitlipid® N (fat-soluble vitamins) and Solvitio® N 
water-soluble vitamins) Adult Injections. There were prepared 6 Bags altogether, 
three with addition of trace elements contained in Additrace® concentrate and three 
Bags without trace elements. Assessing the chemical and physical stability was 
carried out after: zero time, 7, 14 and 29 days in a refrigerator followed by 24 hours 
and 48 hours storage at ambient temperature and day-light protected. Physical tests 
include pH, osmolality, microscopy and particle size determination by laser 
diffraction. Chemical tests used validated stability indicating reversed phase HPLC 
methods. Only four vitamins were suitable for investigation via HPLC: vitamin A, 
vitamin E, riboflavin and pyridoxine. 
 
It was found that pyridoxine is the most stabile vitamin, because its losses were 
negligible. All discussed vitamins are light-sensitive and day-light protection caused 
that losses of these vitamins were multiple less. All vitamins are stable when they are 
stored in a refrigerator for first seven days. If they are stored at ambient temperature, 
stability has decreasing tendency. It was found that vitamin E is rapidly degraded 
when is in the mixture with trace elements. Degradation of vitamin E is not so 
significant when the mixture is trace elements free. The most stable admixtures are 
those stored for seven days in a refrigerator. If they are stored for more than 7 days 
they become potentially unstable because of higher amount of enlarged lipid 
globules. 
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ABSTRAKT 
 
Parenterální výživa je alternativní metoda poskytování nutriční podpory pro pacienty 
prostřednictvím žilního systému. Pacienti vybraní pro parenterální výživu jsou 
podvyživení nebo mají potenciál k podvyživenosti. Směsi parenterální výživy se 
skládají z tuků, sacharidů, proteinů, vitamínů, stopových prvků, elektrolytů a tekutin. 
Vitamíny jsou považovány za nejméně stabilní složky v parenterálních směsích, a 
tudíž by měly být přidány bezprostředně před aplikací infuze. Cílem mé práce bylo 
získat informace o stabilitě vitamínů ve směsích s parenterální výživou v závislosti na 
různých skladovacích podmínkách a na době skladování. 
 
Vitamíny rozpustné ve vodě a v tucích byly testovány ve směsi Kabiven® Bag 
(Fresenius Kabi) s Vitlipid® N emulzí obsahující vitamíny rozpustné v tucích a 
s roztokem obsahujícím vitamíny rozpustné ve vodě - Solvitio® N. Celkem bylo 
připraveno šest směsí, tři s přídavkem stopových prvků obsažených v Additrace® 
koncentrátu a tři bez přídavku stopových prvků. Testování fyzikální a chemické 
stability bylo provedeno v čase přípravy směsí, po 7, 14 a 29 dnech skladování 
v lednici následované 24 a 48 hodinovým skladováním těchto směsí při okolní 
teplotě. Směsi byly chráněny před světlem po celou dobu skladování. Provedené 
fyzikální testy zahrnovaly měření hodnot pH, osmolarity, mikroskopii a měření 
velikosti částic laserovou difrakcí. K chemickým testům byly použity validované a 
stabilitu určující metody HPLC s užitím reverzní fáze. Pomocí HPLC bylo možno 
testovat pouze čtyři vitamíny, konkrétně vitamíny A a E, dále riboflavin a pyridoxin. 
 
Bylo zjištěno, že pyridoxin je nejstabilnější vitamín, protože jeho ztráty v průběhu 
stabilitních studií byly zanedbatelné. Všechny zmiňované vitamíny jsou citlivé na 
světlo. Ochrana před denním světlem způsobila, že ztráty vitamínů jsou tak 
mnohonásobně nižší. Všechny vitamíny se ukázaly být stabilní po dobu prvních 
sedmi dní skladování v lednici. Jestliže jsou směsi uchovávány při okolní teplotě, 
stabilita vitamínů klesá. Bylo zjištěno, že vitamín E rychle degraduje, jestliže je ve 
směsi se stopovými prvky. Degradace vitamínu E není tak zřejmá, jestliže je ve 
směsi prosté stopových prvků. Nejvíce stabilní jsou ty směsi, které se uchovávají 
v lednici po dobu sedmi dní od připravení. Jestliže jsou skladovány déle, stávají se 
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potencionálně nestabilními, kvůli většímu množství zvětšených nežádoucích 
lipidových globulí. 
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